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ABSTRACT

Design and Optimization of a Blood Vessel Mimic Bioreactor System for the Evaluation
of Intravascular Devices in Simple and Complex Vessel Geometries
by
Sara M. Leifer

Coronary artery disease affects millions of people and the ability to detect and
treat the disease is advancing at a rapid rate. As a result, the development of intravascular
technologies is the focus of many medical device manufacturers. Specifically, coronary
stent implantation is being performed in an increasing number of patients and a number
of new stent designs have been introduced to the market, resulting in the need for
improved preclinical testing methods. An in vitro tissue engineered “blood vessel mimic”
(BVM) system has previously been established and its feasibility for the initial testing of
newly emerging intravascular technology has been demonstrated. There are limitations
that exist with this original design, however, and the focus of this thesis was to both
improve and expand upon the original model. Therefore, research was conducted based
on two specific aims. The first aim was to develop a more ideal BVM system to
accommodate a wider range of stent lengths and diameters, while allowing for easy graft
insertion and seal-ability. The second aim was to develop next generation BVM systems,
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focused on future needs and technology, such as long, angulated and bifurcated
geometries.
The work described in this thesis demonstrates that a BVM chamber can be
created which has the advantages of easy graft insertion and seal-ability, as well as the
ability to accommodate varying sizes of vessel scaffolds, all while maintaining the needs
of a tissue engineering bioreactor system. The next generation BVM systems presented
demonstrate that the BVM concept can be expanded to meet the needs of long, angulated
and bifurcated geometries. Overall, the work in this thesis describes the design and
optimization of an in vitro blood vessel mimic bioreactor system for the evaluation of
intravascular devices, specifically coronary stents, in simple and complex vessel
geometries.
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1. INTRODUCTION
Overview
Coronary stent implantation is being performed in a large number of patients with
a wide spectrum of clinical and lesion characteristics. From single and multiple vessel
disease to bifurcated, angulated and long lesions, the variation and complexity of
coronary artery disease and the advanced capabilities to detect and determine the extent
and severity has led to an increased interest in intravascular device innovation (Zhu, et al.
2008; Kini 2006). A variety of stent designs currently exist and continuous efforts are
being made to improve both stent design and placement procedures (Kandzari, Tcheng
and Zidar 2002; Kraitzer, Kloog and Zilberman 2008). Smaller delivery catheters and
advanced delivery systems are also being introduced and have allowed the treatment of
coronary artery disease and stent placement to become less invasive and easier on both
the patient and physician (Yamasaki, et al. 2008; Takeshita, et al. 2008).
With the transition from open heart surgery to balloon angioplasty and stent
placement, minimally invasive procedures have become the most often used technique
for treating many cardiovascular diseases (American Heart Association 2008), which in
turn has lead to a high demand for preclinical assessments of new intravascular devices
(Kandzari, Tcheng and Zidar 2002; Cardinal, et al. 2006). The explosive growth of
coronary stenting has fueled a surge in the number and types of coronary stents and
delivery systems being designed and introduced to the market. Specifically in the area of
coronary stents, a wide range of stent materials, coatings, drugs, and configurations
currently exist, with future developments accelerating at a rapid pace (Kraitzer, Kloog
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and Zilberman 2008). Some of the most exciting advances can be seen in new stents
designed specifically to treat bifurcation lesions, an area that has been very challenging
for physicians, and new delivery systems which can deploy long or multiple stents at one
time in order to better treat patients with long lesions or lesions in multiple vessels
(Ikeno, Buchbinder and Yeung 2007; Stella, et al. 2008). This surge in stent technology
has resulted in the need for new and advanced preclinical testing methods that provide
medical device manufacturers and researchers with the ability to quickly evaluate tissue
response to new and novel stent designs and stenting techniques.
Coronary stents are constantly evolving devices that possess great potential, but
each innovation and each new design that is developed must be fully evaluated before
clinical applications are possible. Through the creation of an in vitro tissue engineered
blood vessel construct, previously developed and called a “blood vessel mimic” (BVM),
a model system can be established for the initial testing of newly emerging intravascular
technology (Cardinal, et al. 2006). The goal of this thesis is to not only expand upon the
original BVM model, but to develop new and innovative models for the evaluation of
devices in more complex geometries such as bifurcations, long and angulated vessels.
The following introduction will provide the background and foundation on which
this thesis is based. A review of coronary artery disease will be given followed by current
diagnosis and treatment procedures. Coronary stents will be discussed in detailed,
outlining the materials utilized, shapes, configurations, coatings and drugs used in their
design. Other intravascular devices, delivery systems and technologies will also be
addressed along with an overview of intravascular device preclinical testing methods and
the BVM system specifically. The introduction will conclude with a summary of the
2

specific aims for this thesis, which will lead into the individual chapters and the models,
experiments and studies that were built and performed.
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Coronary Artery Disease
Pathology
In order to understand why intravascular technologies, specifically stents, have
become the treatment of choice for many cardiovascular diseases, and why the medical
community has focused so much attention on creating and testing intravascular devices to
treat these diseases, one must appreciate the history and prevalence of the disease itself.
Coronary artery disease (CAD), also known as coronary heart disease (CHD), is the
number one killer of both men and women in the United States, affecting an estimated 16
million people (American Heart Association 2008). In 2008 alone, the direct and indirect
cost of treating CAD is estimated at $156.4 billion (American Heart Association 2008),
making it the primary focus of many medical device manufacturers.
The coronary arteries are small blood vessels that run along the surface of the
heart and carry blood which supplies oxygen and nutrients to the heart muscle. The
anatomical characteristics of coronary arteries vary considerably, ranging from straight
simple geometries to extremely angulated bends and curves as well as bifurcations and
long lesions (Ellis, et al. 1990; Zhu, et al. 2008; Smith, et al. 2001). Depending on the
individual, the anatomical structure of the coronary arteries can include all or some of the
characteristics identified above.
Coronary artery disease can be described as atherosclerosis of the coronary
arteries (Falk 2006; Noll 1998). Atherosclerosis occurs when the coronary arteries
become narrowed or blocked by fatty deposits called plaque, restricting blood flow to the
heart (Deconinck, et al. 2008). A healthy artery and an artery affected by atherosclerosis
4

are illustrated below in Figure 1.1. Without adequate blood, the heart becomes starved of
oxygen and vital nutrients it needs to work properly. If left untreated coronary artery
disease leads to chest pain, heart attack, heart failure and ultimately death (American
Heart Association 2008). Therefore, action must be taken to reopen the narrowed vessels
and restore blood flow.

Figure 1.1- Atherosclerosis of the coronary arteries. Plaque accumulation on the artery
wall results in restricted blood flow to the heart.

(Permission granted to reprint image from the National Heart, Lung, and Blood Institute
as a part of the National Institutes of Health and the U.S. Department of Health and
Human Services; see Appendix G)

5

For many years, the process of atherosclerosis has been viewed simply as the
accumulation of lipids within the artery wall, however it is now understood that
atherosclerosis is a complex inflammatory disease (Libby, Ridker and Maseri 2002; Ross
1999; Noll 1998) involving endothelial cells (EC), smooth muscle cells (SMC), Tlymphocytes, B-lymphocytes, monocytes, leukocytes and macrophages (Stoll and
Bendszus 2006; Falk 2006). This new insight into the role of inflammation in the
development of atherosclerosis has initiated important new areas of research in the
treatment of coronary artery disease, most notably in the area of pharmaceuticals
(Deconinck, et al. 2008). As will be discussed in detail, the use of pharmaceuticals on the
surface of stents in an attempt to prevent or slow the progression of atherosclerosis is a
recent technology and an area that is still undergoing research and in need of preclinical
testing options.

Diagnosis
Coronary artery disease develops slowly, often without any signs or symptoms
prior to a heart attack. However, there are a number of symptoms that can help diagnosis
CAD and lead to proper treatment (American Heart Association 2008). The most
common symptom of coronary artery disease is chest pain, also known as angina
pectoris, or simply angina (Khan 2005; Crawford 2002). Angina results from the heart
not getting enough blood and oxygen and is described as chest discomfort, heaviness,
tightness, pressure, aching, burning, numbness, fullness, or squeezing. It is most often felt
in the chest, but may also be felt in the shoulders, arms, neck, back or jaw. Shortness of
6

breath is a second symptom and is most often experienced during physical activity. Due
to long-term lack of blood and oxygen, the heart becomes weak and is unable to pump
blood throughout the body. Other less common symptoms of CAD include heart
palpitations, irregular or rapid heartbeat, weakness, dizziness, nausea, and sweating.
Whatever the symptom, diagnosis is the first step to treatment.
Diagnosis of coronary artery disease begins with a complete review of medical
and family history and a thorough physical examination (Crawford 2002). Although both
these methods can predict the likelihood of an individual’s chance of having the disease a
diagnostic test must be performed in order to verify the diagnosis. Often the first
diagnostic tests chosen are an electrocardiogram (ECG or EKG) or echocardiogram
(ECHO), since these tests are relatively low cost, simple, and non-invasive, providing fast
information about the function of the heart. Stress tests, nuclear imaging, computerized
tomography (CT) scans, positron emission tomography (PET) scans, magnetic resonance
imaging (MRI) and other non-invasive diagnostic tests may also be performed, with
varying degrees of imaging and informational capabilities. Currently, however, one of the
most often used diagnostic tests and the reference against which all other diagnostic
imaging tests are compared is the coronary angiogram, providing a direct image of the
coronary arteries themselves (Budoff, et al. 2008; Sun and Jiang 2006). Coronary
angiography is a minimally invasive imaging procedure in which a catheter is guided into
the coronary arteries, a process often referred to as cardiac catheterization, dye is
injected, and x-ray images are taken as the contrast material moves through the heart’s
chambers, valves and major vessels. The resulting images are used to identify sites of
narrowing or blockage in the coronary arteries and provide a visual picture of the location
7

and severity of coronary artery disease. Coronary angiography is illustrated below in
Figure 1.2.

Figure 1.2- Coronary angiography. A catheter is guided into the coronary arteries, dye is
injected, and x-ray images are taken as the contrast material moves through the heart.

(Permission granted to reprint image from the National Heart, Lung, and Blood Institute
as a part of the National Institutes of Health and the U.S. Department of Health and
Human Services; see Appendix G)

Using angiography alone, however, allows only a limited quantitative analysis of
the vessel lumen blockage from the silhouette image obtained; and although angiography
reveals artery narrowing, it cannot differentiate between the vessel layers or identify the
presence of plaque on the artery walls (Kern, et al. 2006; Wahle, et al. 2006). Therefore,
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more advanced imaging techniques are often performed to supply additional information
about the coronary arteries that angiography alone cannot provide.
Intravascular ultrasound (IVUS) is an imaging procedure that can be performed
simultaneously with coronary angiography in order to obtain detailed images of the walls
of the coronary arteries. During IVUS a miniature sound-probe is positioned on the tip of
a coronary catheter. The catheter is threaded through the coronary arteries and using
high-frequency sound waves detailed images of the inside walls of the arteries are
created. These images show cross-sections of the lumen revealing the layered structure of
the vascular wall and provide information about the composition of the lesions including
plaque shape and size (Cardinal, et al. 2006; Schoenhagen and Nissen 2002).
No matter what technique is used, the goal of coronary imaging is to identify the
location, characteristics, number and severity of lesions present in a patient diagnosed
with coronary artery disease. Treatment decisions are based on these findings and
specific treatment options are available for a number of lesion characteristics. Depending
on the number, severity and location of the blockages found during the diagnostic
procedure, the physician can recommend the appropriate treatment.

9

Treatment of Coronary Artery Disease
Treatment of coronary artery disease can include lifestyle changes, medications,
and medical procedures. The goal of each treatment is to relieve symptoms and reverse or
slow the progression of the disease. Depending on the severity of the disease, a
combination of treatments may be chosen. Although the focus of this thesis is on
interventional medical procedures and intravascular devices, it is important to realize that
if CAD is caught early enough interventional procedures or surgery may not be needed
which is the best scenario for both the patient and physician.

Lifestyle Changes and Medication
Simple lifestyle changes can often help prevent or control CAD and for some
individuals these changes may be the only treatment needed. It is hard to determine
which controllable risk factors are most important but, in general, high cholesterol,
cigarette smoking, excess weight, sedentary lifestyle, high blood pressure, and diabetes
seem to be the most significant (American Heart Association 2008; Crawford 2002).
Therefore, diet changes, avoiding tobacco products, exercise, and weight loss can often
reduce these risk factors and control the onset and development of CAD.
For some individuals, however, lifestyle changes may not be enough and
medication may be prescribed. A number of medications are currently used, each with the
goal of either treating the risk factors associated with CAD or treating the effects of the
disease. Aspirin, a blood thinner, is recommended for almost everyone who has CAD, to

10

help reduce the risk of having a heart attack (Hayden, et al. 2002). Other medications
include: anti-platelet agents and anticoagulants, which prevent the formation of blood
clots and thin the blood; statins, which help lower cholesterol; nitrates and ACE
inhibitors, which dilate the arteries and make it easier for blood to flow; beta-blockers
and calcium channel blockers, which slow the heart rate and reduce blood pressure
(Zoghbi, Dorfman and Iskandrian 2008). Unfortunately, when medications and lifestyle
changes are not able to control symptoms or the narrowing progresses to a point that the
heart muscle is at risk for damage, interventional procedures or surgery may be required.

Coronary Artery Bypass Grafting
A number of surgical procedures and interventional therapies have been
developed over the past several decades to treat coronary artery disease, each with the
goal of quickly and safely restoring blood flow to the heart. Coronary artery bypass graft
surgery (CABG) was developed as a treatment for CAD in the late 1960’s and is still a
frequently used technique today (American Heart Association 2008). In this procedure a
healthy vein or artery is removed from the patient's body and used to bypass the coronary
blockage (Khan 2005; Mullany 2003). The saphenous vein, internal mammary artery and
radial artery are used most often, however when no healthy segment can be found within
the patient’s body a synthetic graft material, such as expanded polytetrafluoroethylene
(ePTFE), can also be utilized (Weyand, et al. 1999).
During CABG the patient's chest is surgically opened and the harvested artery or
vein is connected between the aorta and a healthy area of the heart in order to provide a
11

pathway for the blood to flow around the site of the damaged and narrowed tissue. An
illustration of CABG is shown below in Figure 1.3.

Figure 1.3- Coronary artery bypass grafting. A healthy vein or artery is connected
between the aorta and a healthy area of the heart in order to bypass the coronary blockage
and provide a pathway for blood to flow.

(Permission granted to reprint image from the American Heart Association/American
Stroke Association; see Appendix G)

For many years, CABG had been considered the standard of care for treating
CAD in patients at moderate to high risk of a heart attack (Hamm, et al. 1994). In many
cases CABG is still the best choice of treatment. However, CABG can be a highly
invasive procedure that is generally associated with long recovery times and hospital
stays, as well as high cost (American Heart Association 2008; Mullany 2003). For many
patients open heart surgeries, such as CABG, are not well tolerated and lead to
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complications that are amplified by the heart’s weakened condition. Thus less invasive
methods to treat CAD have been developed.

Balloon Angioplasty

Percutaneous coronary intervention (PCI) is a minimally invasive procedure used
to treat patients with diseased coronary arteries. The initial innovation was balloon
angioplasty, originally referred to as percutaneous transluminal coronary
angioplasty (PTCA). The first balloon angioplasty was performed in 1977 by the Swiss
physician Andreas Gruentzig (King and Meier 2000; Gruentzig 1978) and the basic
technique is still used today. During balloon angioplasty a physician inserts a flexible
catheter with a balloon tip into the patient’s vascular system, most often through the
femoral artery at the groin, and maneuvers the catheter through the vascular system into
the coronary arteries. At the site of the coronary lesion or blockage the balloon is inflated,
compressing the plaque and stretching the artery wall, creating a wider channel and
restoring blood flow to the heart. Balloon angioplasty is illustrated in Figure 1.4 below.
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Figure 1.4- Balloon angioplasty. A flexible catheter with a balloon tip is maneuvered into
the coronary arteries and inflated, compressing the plaque and stretching the artery wall
restoring blood flow to the heart.

(Permission granted to reprint image from the National Heart, Lung, and Blood Institute
as a part of the National Institutes of Health and the U.S. Department of Health and
Human Services; see Appendix G)
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Coronary angioplasty provides physicians with a simple, minimally invasive
method of opening a blocked artery without having to open the patient’s chest. This
therapy has been widely adopted by physicians because it results in shorter hospital and
recovery times compared to CABG and is well tolerated by most patients (American
Heart Association 2008). However, while providing advantages over CABG, the longterm effectiveness of balloon angioplasty is limited by restenosis, or re-narrowing of the
artery. Restenosis is observed to occur due to two primary causes: the elastic recoil of the
artery wall, its shrinkage back to its original size, and neointimal proliferation, the
formation of scar tissue (Kraitzer, Kloog and Zilberman 2008; Deconinck, et al. 2008).
This statement is an oversimplification of the process of restenosis, and restenosis will be
discussed in detail in the following paragraphs, but for now it is important to note these
two key observations as they are part of the motivation for the following advancements in
treatment.

Stenting
One of most significant innovations in percutaneous coronary intervention, and
that which is still evolving today, was the introduction of the stent in the late 1980’s
(Waksman 2002; King and Meier 2000). Stents are tube shaped scaffolds, typically metal
or polymer, which are used to physically hold the artery wall open and address the first
primary cause of restenosis (Kraitzer, Kloog and Zilberman 2008; Kandzari, Tcheng and
Zidar 2002). In an attempt to prevent elastic recoil of the artery wall stents were
incorporated into the balloon angioplasty procedure in the early 1990’s. It is noteworthy
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to mention, however, that the stenting of peripheral arteries had already been
experimented with by Charles Dotter in the 1960’s who hypothesized that the use of
stents in coronary arteries was also possible (King and Meier 2000; Dotter 1969). It
should also be noted that in this section only a basic definition and description of stent
design is addressed. Coronary stents will be discussed in detail in subsequent sections.
During a percutaneous coronary interventional stenting procedure, a stent
mounted on a balloon catheter is delivered to the lesion, or site of narrowing and
blockage. The balloon is inflated expanding the stent, compressing the plaque and
stretching the artery wall. The balloon catheter is then removed, leaving the stent behind
to hold the vessel open, restoring blood flow to the heart. Stent placement is illustrated
below in Figure 1.5.
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Figure 1.5- Stent placement. A stent is mounted on a balloon catheter and maneuvered
into the coronary arteries. The balloon is inflated compressing the plaque, expanding the
stent and restoring blood flow to the heart.

(Permission granted to reprint image from the National Heart, Lung, and Blood Institute
as a part of the National Institutes of Health and the U.S. Department of Health and
Human Services; see Appendix G)
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Bare Metal Stents
In 1986, Jacques Puel and Ulrich Sigwart inserted the first bare metal stent into a
human coronary artery (King and Meier 2000; Sigwart, et al. 1987). Bare metal stents
(BMS) are coil, mesh or slotted tubes consisting of interconnected struts that are inserted
inside the narrowed artery and expanded to hold it open. Stents significantly lowered the
occurrence of restenosis by preventing elastic recoil of the artery wall and quickly
replaced the use of balloon angioplasty as the primary interventional therapy for CAD
(Waksman 2002; King and Meier 2000).
In 1994 the first bare metal stents, Palmaz-Schatz and Gianturco-Roubin, were
approved for use in the United States, and over the next decade, several generations of
bare metal stents were developed. By early 2000, stenting was performed in over 80% of
all PCI procedures reducing the restenosis rate to 15-20% (Holmes, et al. 2002; Waksman
2002; Kandzari, Tcheng and Zidar 2002). Previously, restenosis rates following balloon
angioplasty had been seen in 30-40% of patients (Silverman 2006; Waksman 2002) and
often required re-intervention by physicians. Unfortunately, despite their widespread use,
bare metal stents are plagued by the occurrence of in-stent restenosis, re-narrowing of the
artery around the stent, with patients showing clinical evidence within the first 3-9
months after implantation (Holmes, et al. 2002). In-stent restenosis around an implanted
stent is illustrated in Figure 1.6 below.
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Figure 1.6- In-stent restenosis. Re-narrowing of the artery around the stent.

(Permission granted to reprint image from the National Heart, Lung, and Blood Institute
as a part of the National Institutes of Health and the U.S. Department of Health and
Human Services; see Appendix G)

Restenosis
Restenosis is defined as the arterial healing response after injury incurred during
coronary angioplasty (Lowe, Oesterle and Khachigian 2002; Indolfi, et al. 2003). In-stent
restenosis (ISR) is defined as the arterial healing response due to injury incurred during
coronary angioplasty and the presence a stent. Both restenosis and in-stent restenosis are
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the result of a complex series of biological events in response to the initial injury of the
vessel caused by balloon expansion and the presence of a permanent stent implant
(Lewis, Tolhurst and Stratford 2002).
The process of restenosis involves vessel elastic recoil, negative remodeling,
thrombus, smooth muscle cell proliferation, and excessive extracellular matrix production
(Weintraub 2007). Neointimal formation, also known as neointimal proliferation, is one
of the main mechanisms of restenosis and composed mainly of proliferating smooth
muscle cells and extracellular matrix formation (Lowe, Oesterle and Khachigian 2002).
In addition, inflammatory responses, foreign body reactions, and thrombogenesis occur in
the tissue surrounding the struts of the stent and contribute to in-stent restenosis
(Karoussos, et al. 2002). In-stent restenosis is a major clinical problem associated with
stenting. Therefore, many efforts are being made to reduce or eliminate its occurrence.
In recent years, drug eluting, coated and bioabsorbable stents have been
introduced into interventional cardiology as a possible solution to the problem of in-stent
restenosis. Researchers and medical device manufacturers are continuously testing a
variety of drugs that are known to interrupt the biological processes that cause restenosis
(Deconinck, et al. 2008; Kraitzer, Kloog and Zilberman 2008). Stent coatings can
optimize the surface properties of metallic stents and serve as a vehicle for local drug
delivery (Hara, et al. 2006). Biodegradable materials can be absorbed by the body,
allowing a stent to act as a scaffold for a period of time and then slowly disappear once it
is no longer needed (Mani, et al. 2007). As a result the evolution of the stent has moved
away from being a purely mechanical object placed within the artery. With
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pharmacologic and material advances, stents have become active devices that interact
with their environment in complex ways.

Drug Eluting Stents
A recent innovation in percutaneous coronary intervention is the development of
drug eluting stents (DES). Drug eluting stents address the second basic cause of
restenosis by attempting to prevent or slow neointimal proliferation and the formation of
scar tissue at the lesion site (Kraitzer, Kloog and Zilberman 2008; Waksman 2002; Lowe,
Oesterle and Khachigian 2002). A drug eluting stent is a device that releases a single or
multiple bioactive agents into the bloodstream that affect the tissue adjacent to the stent.
The drugs used inhibit cell growth and proliferation and this advancement has resulted in
improved patient outcomes due to reduced in-stent restenosis (Popma, et al. 2007). The
specific drugs used to prevent restenosis and their incorporation into stent design will be
discussed in detail in the following sections.
In 2001, drug eluting stents (DES) were introduced into percutaneous coronary
interventional procedures as a strategy to minimize in-stent restenosis due to neointimal
proliferation (Kraitzer, Kloog and Zilberman 2008; Deconinck, et al. 2008). In the data
gathered so far drug eluting stents have been extremely successful in reducing in-stent
restenosis rates from 15-20% to single digits (Holmes, et al. 2002; Waksman 2002;
Kandzari, Tcheng and Zidar 2002). At present, 90% of all stents placed in the United
States are drug eluting (Popma, et al. 2007). One disadvantage, however, is the
development of late in-stent restenosis and thrombosis, which occur after the drug has
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been completely eluted and is no longer present in the coronary stent (Deconinck, et al.
2008; Waksman 2007).

Bioabsorbable Stents
Despite the development and progression of bare metal and drug eluting stents,
many concerns still remain regarding their permanent nature and influence on restenosis
(Waksman 2007; Sharkawi, et al. 2007). Thus, bioabsorbable stents have emerged as an
alternative to permanent metallic stents. Bioabsorbable stents, also described as
biodegradable or bioresorbable, are constructed of metallic or polymer materials that
degrade over time into substances that can be slowly absorbed by the body (Ormiston, et
al. 2008; Erbel, et al. 2007). The specific materials used to create biodegradable stents
will be discussed in the following sections. Bioabsorbable stents perform much like other
coronary stents except that they are made of biodegradable materials that can be absorbed
by the body, allowing them to initially act as supportive scaffolds while slowly
disappearing as the vessel heals. The promise behind their technology lies in the fact that
they provide a short term vessel scaffold, which can also be used for local drug delivery,
and are then absorbed by the body avoiding the long term negative effects of permanent
metallic stents such as in-stent restenosis and thrombosis. Currently biodegradable stents
are not approved for clinical use in the United States (Ormiston, et al. 2008), however,
clinical trials and research into their development are ongoing and release is expected in
the near future.
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Complex Lesions
Many stents in the market today are designed and indicated for use in simple,
straight, short lesions (Fournier, et al. 2005). However, in clinical practice coronary
arteries are not straight and uniform. They run along the surface of the heart and are
curved, bent, and angulated (Smith, et al. 2001). As a result, coronary stent implantation
is being performed in an increasing number of patients with complex lesion
characteristics including long, angulated and bifurcated lesions.
Coronary lesions are often extremely long in length and treatment can require
multiple overlapping stents (Ruchin, et al. 2008). Therefore, new interlocking stent
designs, such as the Custom NX(R) DES System manufactured by XTENT, Inc., are
exploring the possibility of deploying stents up to 60 mm in total length (Stella, et al.
2008). It has also been observed that plaque accumulation is related to vessel curvature,
with plaque accumulating more rapidly in angulated vessels where wall shear stress is
low (Wahle, et al. 2006; Zhu, et al. 2008). Therefore, stents are most often placed in
curved positions within the coronary arteries and remain in a bent position throughout
their lifetime (Fournier, et al. 2005; Smith, et al. 2001). Many coronary stents, such as the
MULTI-LINK manufactured by Abbott Vascular, CYPHER® manufactured by Cordis,
and TAXUS® manufactured by Boston Scientific, claim superior flexibility and
conformity which allow the stent to mold to the natural contours of the vessel wall
(Serruys and Gershlick 2005; Rieu, et al. 2003). Consequently, accommodation of
complex bends and geometries is being taken into greater consideration in overall stent
design.
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A coronary bifurcation lesion is defined as a narrowing involving both the main
vessel and a significant side branch (Louvard, et al. 2008). Bifurcation lesions account for
15-18% of all coronary lesions and represent one of the most complex coronary lesions to
treat since the lumen of both the main vessel and side branch are affected and require
treatment (Sukhija, Mehta and Sachdeva 2008). As described by the American College of
Cardiology/American Heart Association (ACC/AHA) Guidelines for Percutaneous
Coronary Intervention a coronary bifurcation occurs when one main vessel branches out
into two smaller vessels, one being the continuation of the main vessel, and the other
referred to as the side branch (Smith, et al. 2001). Recent advances have allowed
physicians to treat bifurcation lesions, where both the main vessel and side branch need
to be restored.
Many techniques, with the use of single or multiple stents, have been developed
to treat bifurcation lesions (Sukhija, Mehta and Sachdeva 2008; Iakovou, Ge and
Colombo 2005). The simplest approach is to stent the main vessel and dilate the side
branch through the stent struts. A second approach is to use multiple stents and can be
accomplished through a number of different techniques. V-stenting involves the delivery
and implantation of two stents, one in each bifurcation branch. The simultaneous kissing
technique is similar to V-stenting in that two stents are implanted, one in each branch,
with the difference being that the two stents touch and extend into the main branch.
Crush, T-stenting and modified T-stenting techniques require two stents to be positioned
perpendicular to each other, and while the techniques vary, the resulting stent
configurations are identical. Y-stenting involves the delivery and implantation of three
stents, one in each bifurcation branch and one in the main branch. Finally, the skirt
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technique involves the delivery and implantation of one, two or three stents with the
bottom half of the stent dilated to a larger diameter than the top. The bifurcation stenting
techniques described are illustrated below in Figure 1.7.

a)

b)

c)

d)

e)

f)

Figure 1.7- Bifurcation stenting techniques. V-stenting (a), simultaneous kissing (b),
crush (c), T-stenting and modified T-stenting (d), Y-stenting (e) and skirt (f).

(Permission granted to reprint image from Iakovou, Ge and Colombo 2005 published in
Journal of the American College of Cardiology by Elsevier Limited.; see Appendix G)

Most recently, novel stents and delivery systems such as AXXESS™
manufactured by Devax, Inc., PETAL™ manufactured by Boston Scientific, and
MULTI-LINK Frontier manufactured by Abbott Vascular have been developed
specifically to treat bifurcation lesions (Grube, et al. 2007; Ikeno, Buchbinder and Yeung
2007; Lefèvre, et al. 2005). These stents have the potential to provide physicians with a
method to treat complex bifurcation lesions, resulting in better procedural outcomes and
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overcoming some of the technical difficulties associated with treating these complex
lesions.
In summary, the variation and complexity of coronary artery disease and the
advanced capabilities to detect and determine the extent and severity of coronary lesions
has led to an increased interest in intravascular device innovation (Kini 2006). With the
development of drug eluting and bioabsorbable stents, new drugs and materials are being
introduced at an extremely rapid pace (Kraitzer, Kloog and Zilberman 2008). Each new
drug and material must be evaluated for biocompatibility and tissue response and the
competitive nature of biotechnology has the medical community searching for testing
methods and procedures that provide rapid and reliable results.
The blood vessel mimic system has the potential to fulfill this preclinical testing
need (Cardinal, et al. 2006). Ideally the BVM system will provide a means to rapidly
evaluate human tissue response to varying stent configurations, materials, drugs and
coatings as they become available. The safety of drug eluting and bioabsorbable stents, as
well as stents designed specifically to treat complex lesions, is still an area of active
research (Popma, et al. 2007). However, one thing remains clear- as the understanding of
stent and tissue interactions continue to increase, the need to quickly evaluate new
pharmacologic agents, configurations and materials will grow, and the need for a model
system such as a BVM will be critical for preclinical device testing.
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Intravascular Technology
Coronary Stents
The types and construction of coronary stents is an area of active research and
stents are constantly undergoing evolution in terms of the materials utilized, geometrical
configurations, sizes, and coatings (Sangiorg, et al. 2007; Hara, et al. 2006; Kandzari,
Tcheng and Zidar 2002). Stents have evolved from simple coil and slotted tubes to
complex configurations with active coatings and advanced features. The current BVM
system is a means of evaluating tissue response to varying stent surfaces, coatings, and
drugs as well as an evaluation of the physical stents themselves (Cardinal, et al. 2006).
The BVM system is designed to test a variety of stent lengths and diameters with varying
configurations and coatings, and knowledge of stent design is fundamental for
understanding the needs of the system in order to physiologically mimic coronary arteries
and induce representative cell response. Therefore, it is necessary to understand the
general design and features of stents available in the market today.

Mechanism of Expansion
Stents can be divided according to their mechanism of expansion into two main
categories: balloon-expandable and self-expanding (Kraitzer, Kloog and Zilberman 2008;
Morton, Crossman and Gunn 2004). Balloon-expandable stents are made from materials
that can be plastically deformed through the inflation of a balloon. The stent is mounted
on the tip of a balloon catheter and the inflation of the balloon causes the stent to expand.
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Once the balloon is deflated the stent remains in its expanded shape inside the vessel.
Self-expanding stents, on the other hand, are manufactured in their expanded shape, then
compressed and constrained in a delivery system. Upon release from the delivery system
they spring back to their manufactured shape. Both balloon-expandable stents and selfexpanding stents are readily available in the market; however, balloon-expandable stents
are more common. A list of coronary stents and their mechanism of expansion is given in
Table 1.1.

Materials
In order to provide effective treatment for coronary artery disease, the ideal stent
material must be flexible, fatigue resistant, expandable, corrosion resistant, biocompatible
and visible under standard medical procedures (Poncin and Proft 2003). Currently the
most widely used material for coronary stents is stainless steel, typically 316L (Mani, et
al. 2007; Sangiorg, et al. 2007; Hara, et al. 2006). Stainless steel is both biocompatible
and corrosion resistant. In its fully annealed condition, stainless steel is easily deformable
and the standard material for balloon-expandable stents. In its full-hard condition it can
also exhibit enough elasticity for some self-expanding stent designs.
Although stainless steel is the most commonly used stent material, several other
materials are currently used, with many more in development. A list of coronary stents
and the material utilized for their construction is given in Table 1.1. The materials most
commonly used by stent manufacturers today, after stainless steel, include cobalt
chromium alloys, tantalum alloys, nitinol, and various polymers (Mani, et al. 2007;
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Morton, Crossman and Gunn 2004). Cobalt chromium is more biocompatible than
stainless steel and is being increasingly used by coronary stent manufacturers
(Hagemeister, et al. 2005). Cobalt chromium alloys are similar in strength to stainless
steel, but have the advantage of being more radiopaque, allowing for the design of thinner
struts without compromising visibility (Kandzari, Tcheng and Zidar 2002). Nitinol, an
alloy of nickel and titanium, is also a common material for coronary stents (Poncet 2005).
With its shape memory technology, nitinol is most often used in self-expanding stents.
Pure iron and magnesium alloys are two metals that are under development for
use in bioabsorbable coronary stents (Mani, et al. 2007; Erbel, et al. 2007; Waksman
2007; Waksman, et al. 2008). Bioabsorbable metallic stents look promising but their long
term biocompatibility still needs to be studied since the elevated local concentration
effects of these elements is unknown. In addition to metallic bioabsorbable stent
materials, polymers such as poly-L-lactic acid (PLLA), polyglycolic acid (PGA),
polylactic-co-glycolic acid (PLGA), poly-D,L-lactic acid (PDLA) and polycaprolactone
(PCL) show potential for use in bioabsorbable stents (Ormiston, et al. 2008; Sharkawi, et
al. 2007; Waksman 2007). Further research is required, however, in order to better
understand the varying tissue responses to these materials.
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Stent Name

Manufacturer

Type

Material

Abbott

Bare Metal

Cobalt Chromium

Abbott

Bare Metal

Stainless Steel

Abbott

Bare Metal

Stainless Steel

Dexamet

Abbott

Drug Eluting

Stainless Steel

FlexMaster

Abbott

Coated

Stainless Steel

TriMaxx

Abbott

Bare Metal

ZoMaxx

Abbott

Drug Eluting

XIENCE V

Abbott

Drug Eluting

Cobalt Chromium

BVS

Abbott

Bioabsorbable
Drug Eluting

Polylactic Acid (PLA)

Drug Eluting

Stainless Steel

Drug Eluting

Platinum Chromium

Bare Metal

Stainless Steel

MULTI-LINK
VISION®
MULTI-LINK
PIXEL®, ZETA®,
ULTRA™
MULTI-LINK
FRONTIER

Stainless Steel
Tantalum
Stainless Steel
Tantalum

Boston
Scientific
Boston
Scientific
Boston
Scientific
Boston
Scientific
Boston
Scientific
Biocompatibles
Cardiovascular
Bioabsorbable
Therapeutics

CYPHER®

Cordis

Drug Eluting

Stainless Steel

AXXESS™

Devax, Inc.

Drug Eluting

Nitinol

TAXUS® Express2
TAXUS® Petal™
Express2
Liberté
PROMUS™
BiodivYsio™
Whisper™

Bare Metal

Stainless Steel

Drug Eluting

Cobalt Chromium

Drug Eluting

Stainless Steel

Bioabsorbable
Drug Eluting

Salicylic Acid

Endeavor

Medtronic

Drug Eluting

Cobalt Chromium

Blazer

OrbusNeich

Bare Metal

Cobalt Chromium

R-Stent

OrbusNeich

Bare Metal

Stainless Steel

Carbostent™

Sorin
Biomedica

Coated

Cobalt Chromium

Custom NX(R)

Xtent

Drug Eluting

Cobalt Chromium

Expansion
Mechanism
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Self-Expanding
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable
Balloon
Expandable

Lesion Type
Small Vessel
Small Vessel
Large Vessel
Bifurcation
Small Vessel
Small Vessel
Small Vessel
Small Vessel
Small Vessel
Small Vessel
Small Vessel
Bifurcation
Small Vessel
Small Vessel
Large Vessel
Small Vessel
Small Vessel
Small Vessel
Small Vessel
Bifurcation
Small Vessel
Small Vessel
Small Vessel
Small Vessel
Small Vessel

Table 1.1- Coronary stent type, material and mechanism of expansion.

Data gathered from references cited throughout text.
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Geometry and Configuration
Coronary stents come in a variety of different geometrical configurations. Early
stent designs were generally classified as either slotted tube or coil geometries (Morton,
Crossman and Gunn 2004). Slotted tube designs were simply metal tubes in which slots
or sections were cut out, leaving open patterns. Coiled stents, on the other hand, were
made of wire or sheet metal fashioned into tube-like structures. Early coiled and slotted
tube stents are shown below in Figure 1.8.

a)

b)
Figure 1.8- Early coronary stent designs. Coiled (a) and slotted tube (b) geometries.

(Permission granted to reprint image from Ruygrok 1997 published in The Asia Pacific
Heart Journal by Elsevier Limited.; see Appendix G)
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While slotted tube designs had excellent radial strength, they lacked flexibility;
the opposite occurred for coil designs (Sangiorg, et al. 2007; Morton, Crossman and
Gunn 2004). The resulting evolution of stent design gave way to the development of a
large variety of stent geometries and configurations including coils, wire mesh, slotted
tubes, corrugated, and interconnected rings. Currently, the majority of stents in clinical
practice are classified as slotted tube or cellular designs which are either laser-cut from a
metal tube or composed of interconnected wire rings (Morton, Crossman and Gunn 2004;
Lau, et al. 2004). Common stent geometries are shown below in Figure 1.9.

a)

b)

c)

d)

Figure 1.9- Current coronary stent designs. Sorin Carbostent (a), Medtronic beStent 2 (b),
Cordis BxVelocity (c), and Boston Scientific Multilink Tetra (d).

(Permission granted to reprint image from Colombo, Stankovic and Moses 2002
published in Journal of the American College of Cardiology by Elsevier Limited.; see
Appendix G)
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As stated in the previous section, novel stents have been developed specifically to
treat bifurcation lesions (Ikeno, Buchbinder and Yeung 2007). These stents have varying
configurations including branches, holes, and other geometrical features that allow for
stenting of both the main branch and side branch. Several of the new bifurcation stent
designs employ an innovative Y-shaped or T-shaped geometry in order to match the
anatomy of lesions that form at the junctions of coronary arteries. The PETAL™
bifurcation stent manufactured by Boston Scientific is shown below in Figure 1.10.

Figure 1.10- Bifurcation stent design. PETAL™ bifurcation stent manufactured by
Boston Scientific.

(Permission granted to reprint image from Ikeno, Buchbinder and Yeung 2007 published
in Cardiovascular Revascularization Medicine by Elsevier Limited.; see Appendix G)
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Different stent designs yield varying tissue responses following implantation
(Hara, et al. 2006) and reasearch concerning the relation of stent geometry, strut thickness
and in-stent restenosis is ongoing. These design variations, as well as the desire to better
understand the impact of stent characteristics on tissue response, result in a need for
preclinical testing environments that support a range of stent shapes, geometries and
configurations.

Diameter and Length
Coronary stents come in varying diameters and lengths (Kraitzer, Kloog and
Zilberman 2008). A list of coronary stents along with their diameters and lengths is given
in Table 1.2. The most common diameters available include: 2.00 mm, 2.25 mm 2.50
mm, 2.75 mm, 3.00 mm, 3.50 mm, 4.00 mm, 4.50 mm and 5.00 mm. The most common
lengths include: 8 mm, 12 mm, 13 mm, 15 mm, 18 mm, 23 mm, 28 mm, 33 mm, and 38
mm. Some of the most recent designs, such as the Custom NX(R) DES System
manufactured by XTENT, Inc., allow physicians to choose the appropriate stent length
while inside the artery at the site of the lesion (Stella, et al. 2008). This variation results
in a need for preclinical testing environments that support a range of stent sizes, ideally
2.0-5.0 mm diameters and 8-38 mm lengths (Kandzari, Tcheng and Zidar 2002; Kraitzer,
Kloog and Zilberman 2008), in order to fit the variations of coronary arteries observed in
clinical practice and the stents currently available in the market.
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Coatings
The surface properties of coronary stents significantly influence tissue response
(Mani, et al. 2007). For this reason, coatings are often applied to metallic stents in order
to change their surface properties and improve biocompatibility. These modifications can
also inhibit neointimal proliferation and thrombosis, which can in turn reduce the rate of
restenosis (Lau, et al. 2004). A list of coronary stents and the type of coating applied is
given in Table 1.2.
The main advantage of a stent coating is the combination of mechanical stability
and increased biocompatibility (Mani, et al. 2007). Coatings are a film of material bonded
to the metallic surface of the stent, or embedded within the porous structure, and can be
either passive or active. Passive coatings are inert and non-reactive in the body, while
active coatings induce a biological response (Karoussos, et al. 2002). Many
considerations must be taken into account when applying a stent coating including the
biocompatibility, long-term effects, and material properties. In addition, it has been
shown that stent coatings should not substantially enhance strut thickness because this
promotes neointimal proliferation (Wieneke, et al. 2003).
Organic coatings include both biodegradable polymers, including PLLA, PGA,
PLGA, PDLA, and PCL as discussed previously, and non-biodegradable polymers.
Polymer coatings have been proposed to improve the biocompatibility of metallic stents
and to serve as a matrix for drug delivery (Karoussos, et al. 2002). Phosphorylcholine
(PC) based polymer coatings, unlike many other polymer coatings, do not provoke
excessive inflammatory or adverse reactions and provide a useful drug delivery platform,
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especially for controlled release of drugs (Mani, et al. 2007; Waksman 2002). Other nonbiodegradable polymers for the potential use in controlled drug release include
hyaluronic acid (HA), polyethylene-co-vinyl acetate (PEVA) and poly n-butyl
methacrylate (PBMA).
There are many inorganic coating materials which are suitable as stents coatings.
Gold, silicon carbide, aluminum oxide and diamond-like carbon are some of the most
common (Mani, et al. 2007). Gold is highly radiopaque and has been shown to be very
biocompatible and significantly reduce neointimal proliferation and thrombosis.
However, clinical studies have shown that gold coated stents increase the risk of
restenosis (Karoussos, et al. 2002; vom Dahl, et al. 2002). Silicon carbide is a passive
stent coating, which has been shown to decrease thrombosis and increase
biocompatibility. Even so, silicon carbide coatings do not significantly reduce restenosis
and do not have any known clinical advantage over other stent coatings (Hara, et al.
2006). Porous ceramic coatings have become very promising for use as drug delivery
platforms. The most recent development is a ceramic aluminum oxide coating with a
unique nanoporous surface (Kang, et al. 2007; Wieneke, et al. 2003). Inorganic ceramic
nanoporous aluminum oxide coatings have been shown to reduce neointimal proliferation
and are specifically designed for incorporation of anti-restenosis drugs, which will be
discussed in detail in the following sections. Lastly, carbon coated stents are coated with
pure diamond-like carbon which is characterized by a polycrystalline structure and shown
to improve biocompatibility (Mani, et al. 2007; Karoussos, et al. 2002). Currently,
however, carbon coatings are not common in clinical use.
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Drugs
The ideal agent for incorporation into drug eluting stents should have potent antirestenosis effects while preserving vascular healing (Kraitzer, Kloog and Zilberman
2008). Anti-inflammatory, anti-thrombogenic, anti-proliferative, and immunosuppressive
agents which interfere with early stages of the cell cycle are currently used in coronary
stent designs to prevent or slow the progress of in-stent restenosis. Each of these agents
inhibits one or more of the biological processes involved in restenosis and have
revolutionized the treatment of coronary artery disease (Waksman 2002). Table 1.2
provides a list of coronary stents and the drugs incorporated into their designs.
Paclitaxel, synthetically produced as Taxol, is a potent inhibitor of cell
proliferation and prevents mitosis of cells during the G2-M phase of the cell cycle (Hara,
et al. 2006). The cell cycle consists of five basic steps: mitosis (M), gap phase 1 (G1),
dormancy (G0), synthesis (S) and gap phase 2 (G2). G2-M is the transition in the cell
cycle from state G2, where the cell produces enough proteins to divide, to state M, where
the cell divides into two daughter cells. Paclitaxel acts by binding to microtubules during
the G2 phase, thus preventing mitosis and cell replication. As a result, it inhibits smooth
muscle cell proliferation and smooth muscle cell migration and has been shown to reduce
inflammation (Deconinck, et al. 2008). Sirolimus, also known as rapamycin, its
analogues zotarolimus and everolimus, and ABT-578 which is a synthetic analogue of
rapamycin, block cell cycle progression at the G1-S transition (Kraitzer, Kloog and
Zilberman 2008). G1-S is the transition in the cell cycle between phase G1, where the
cell increases in size while producing proteins and RNA, to phase S when DNA
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replication occurs. As a result, it inhibits smooth muscle cell proliferation as well as Tcell and B-cell proliferation. Sirolimus and its derivatives are also known to prevent
smooth muscle cell migration and reduce inflammation (Deconinck, et al. 2008; Mani, et
al. 2007). An illustration of the cell cycle is shown below in Figure 1.11 identifying the
cell cycle transition phase inhibited by both paclitaxel and sirolimus.

Figure 1.11- Cell Cycle. Sirolimus blocks cell cycle progression at the G1-S transition
while paclitaxel prevents mitosis of cells during the G2-M transition.

(Permission granted to reprint image from Hara, et al. 2006 published in Advanced Drug
Delivery Reviews by Elsevier Limited.; see Appendix G)

Other common agents for incorporation into drug eluting stents include tacrolimus
(FK506), dexamethasone, and heparin (Deconinck, et al. 2008; Kraitzer, Kloog and
Zilberman 2008). Tacrolimus and dexamethasone are both cellular proliferation
inhibitors. Tacrolimus prevents the proliferation of T-cells, lymphocytes and smooth
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muscle cells. Dexamethasone is a well established anti-inflammatory agent and inhibits
the proliferation of fibroblasts, smooth muscle cells and macrophages. Heparin, an
anticoagulant, reduces leukocyte and platelet adhesion and protects against stent
thrombosis (Mani, et al. 2007; Hara, et al. 2006). It also prohibits smooth muscle cell
migration and proliferation.
Localized drug delivery using stents as the drug delivery platform is advantageous
since the drug is release at the precise location and at the time of vessel injury (Kraitzer,
Kloog and Zilberman 2008). In addition, higher local concentrations are achievable with
little risk of system toxicity. Currently there are three different approaches to binding
drugs to coronary stents: drug binding by means of a polymer on the stent surface, drug
binding aided by an inorganic stent coating, or direct drug binding to the stent surface
without coating (Acharya and Park 2006). Drugs are most often either chemically bonded
to the surface of the stent or trapped within a polymer film or porous ceramic that allows
controlled drug release (Kandzari, Tcheng and Zidar 2002). Drug release in
biodegradable coatings is achieved through disintegration of the biodegradable polymer
of the stent, while non-biodegradable coatings release drugs by allowing the drugs to
diffuse through a porous matrix.
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Stent Name
MULTI-LINK
VISION®
MULTI-LINK
PIXEL®, ZETA®,
ULTRA™
MULTI-LINK
FRONTIER

Manufacturer
Abbott
Abbott
Abbott

Dexamet

Abbott

FlexMaster

Abbott

TriMaxx

Abbott

ZoMaxx

Abbott

Diameter (mm)

Length (mm)

Coating

Drug

2.0,2.25,2.5
2.75,3.0,3.5,4.0
2.0,2.25,2.5
2.75,3.0,3.5
4.0,4.5, 5.0

8,12,15
18,23,28

None

None

8,13,15,18
23,28,33,38

None

None

2.5,3.0,3.5,4.0
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None

None

2.0,2.25,2.5
2.75,3.0,3.5,4.0
2.5,2.75
3.0,3.5,4.0
2.25,2.5,2.75
3.0,3.5,4.0

7,8,10,11,15
18,22,28
9,12,16
19,23,26
8,13,15
18,23,28

Phosphorylcholine (PC)

Dexamethasone

None

Heparin

None

None

NA

NA

Phosphorylcholine (PC)

Zotarolimus
Everolimus
Everolimus

XIENCE V

Abbott

2.5,2.75
3.0,3.5,4.0

8,12,15
18,23,28

Polyvinylidene Fluoride
(PVDF)
Hexafluoropropylene
(HFP)

BVS

Abbott

NA

NA

None

Boston
Scientific
Boston
Scientific
Boston
Scientific
Boston
Scientific

2.5,2.75
3.0,3.5

8,12,16,20
24,28,32

NA

NA

Polystyrene-bisobutylene-b-styrene
Polystyrene-bisobutylene-b-styrene

2.75,3.0,3.5
4.0,4.5,5.0

8,12,16
20,24
8,12,16,20
24,28,32

PROMUS™

Boston
Scientific

2.5,2.75
3.0,3.5,4.0

BiodivYsio™

Biocompatibles
Cardiovascular
Bioabsorbable
Therapeutics
Conor
Medsystems

TAXUS® Express2
TAXUS® Petal™
Express2
Liberté

Whisper™
Conor Medstent™

2.5, 2.75

Paclitaxel
Paclitaxel

None

None

None

None

8,12,15
18,23,28

Polyvinylidene Fluoride
(PVDF)
Hexafluoropropylene
(HFP)

Everolimus

NA

NA

Phosphorylcholine (PC)

Dexamethasone

NA

NA

None

Sirolimus
Salicylic Acid

NA

NA

Polylactide-co-glycolic
Acid (PLGA)
Polyethylene-co-vinyl
Acetate (PEVA)
Poly-n-butyl
Methacrylate (PBMA)

Paclitaxel

CYPHER®

Cordis

2.5,2.75
3.0,3.5

8,13,18
23,28,33

ACHIEVE™

Cook

NA

NA

None

Paclitaxel

AXXESS™

Devax, Inc.

NA

NA

Polylactic Acid (PLA)

Biolimus A9®

Endeavor

Medtronic

NA

NA

Phosphorylcholine (PC)

Zotarolimus

Blazer

OrbusNeich

None

OrbusNeich

9,13,15
18,23,28,33
9,13,15
18,23,28,33

None

R-Stent

2.5,2.75
3.0,3.5,4.0
2.5,2.75
3.0,3.5,4.0

None

None

Janus Carbostent™

Sorin
Biomedica

NA

NA

Carbon

Tacrolimus

Custom NX(R)

Xtent

NA

36,60

Polylactic Acid (PLA)

Biolimus A9®

Table 1.2- Coronary stent diameters, lengths, coatings and drugs.

Data gathered from references cited throughout text.
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Sirolimus

There are many different stent coatings and drugs being researched today and
only the most promising were addressed in this section. Those in clinical use at the
present time are being perfected and many new and different coatings and drugs will be
developed in the future. Tables 1.1 and 1.2 illustrate the various combinations of
geometries, sizes, coatings, and drugs currently available in the market as well as those
being designed for future clinical use. Many of these stents are currently undergoing
clinical trials and are likely to be released in the near future. Others are still in the initial
design phases and in need of a preclinical testing environment such as the BVM system.

Delivery Systems
In addition to the advancements in coronary stent design, the method of delivering
these therapies has also improved. These improvements have made percutaneous
coronary interventional procedures easier to perform and have reduced the amount of
time for a single procedure. Over-the-wire delivery systems represented the first
significant innovation in PCI procedures (Abrams, Baum and Pentecost 2006; Simpson,
et al. 1982). Over-the-wire delivery systems allow manipulation of the guidewire
independently from the balloon catheter. Rapid exchange, or monorail, delivery systems
represent the next advancement and were developed to simplify the exchange of catheters
by allowing a much shorter length of guidewire to be used. Rapid exchange delivery
systems allow a single operator to manage both the catheter and the guidewire during a
PCI procedure (Bonnett, et al. 2004).
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Stent delivery and implantation in complex coronary geometries is a challenge for
conventional delivery systems. It is often difficult to maneuver 6 French catheters, the
current standard for most stent delivery devices, through tortuous vessel geometries
(Saeed, Banerjee and Brilakis 2008). The French catheter scale is commonly used to
measure the outer diameter of cylindrical medical instruments, with one French
equivalent to 0.013 inches. As a result, a novel 4 French balloon catheter was designed
for the treatment of a variety of coronary artery lesions and provides a less invasive
method of treatment while improving procedural outcomes (Takeshita, et al. 2008). The
CardioMind Sparrow™ coronary stent delivery system manufactured by CardioMind is
another low profile delivery device consisting of a self-expanding nitinol stent loaded
into a 0.014 inch guidewire platform with the ability to travel through tortuous
geometries (Yamasaki, et al. 2008; Abizaid, et al. 2007).
In addition to tortuous vessel geometries and the need for lower profile and more
flexible delivery systems, complex coronary lesions often require high-pressure balloon
inflation for complete stent and lumen expansion. The use of high-pressure balloon
inflation has been associated with an increased incidence of restenosis due to injury
caused by balloon inflation (Oesterle, et al. 1998). Therefore, novel low-pressure dilation
balloon catheters, such as the FX miniRAIL manufactured by X Technologies, are being
explored as a method to reduce the balloon pressure required for stent expansion in
complex coronary lesions (Ischinger, Solar and Hitzke 2003).
Percutaneous coronary intervention in complex coronary geometries is difficult
and the increased complexity results in reduced success rates (Saeed, Banerjee and
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Brilakis 2008). Therefore, novel delivery systems, smaller catheters, lower profile
balloons and other devices have been created to overcome the challenges associated with
tortuous anatomies. Stent delivery is an area of active research and a living model system
for testing and evaluating these new delivery devices would be ideal for development and
progression of the field.
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Preclinical Device Testing
Preclinical device testing is a crucial step in the process of developing and
releasing new medical devices to the market. The objective of preclinical testing is to
provide preliminary evidence of product safety and efficacy in order to support the
initiation of human clinical trials (Wall and Shani 2008). Preclinical testing typically
begins using models and methods that are simple and cost-effective in order to identify
potential failures as early in the development process as possible, and then progresses to
models with increasing complexity. Preclinical intravascular device testing is currently
performed using laboratory models, in vitro cellular models, and in vivo animal models
and provides critical information about cellular and tissue responses as well as device
success.

Laboratory Models
One of the first steps in preclinical intravascular device testing involves the use of
laboratory models. Prior to determining the cellular response to a device research must be
performed in order to verify device functionality. Laboratory models are often used to
physically mimic the geometry of coronary arteries and allow a large number of device
designs to be evaluated quickly and inexpensively. For example, synthetic models in
which vessel shaped troughs are bored through plastic blocks are often constructed for
preclinical testing of stents in order to simulate device expansion and delivery within a
coronary vessel (Ormiston, et al. 1999). Other models use flexible tubing to mimic the
vascular structure of the coronary arteries and foam-like material to represent and mimic
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the presence of a lesion (Connolley, et al. 2007). These types of synthetic model
approaches allow stents to be deployed and evaluated in coronary geometries; however,
no cellular lining exists to provide physiological response evaluations.
It is important to remember that stent implantation is a mechanical intervention
and the engineering aspects and mechanical performance of the stent design must be
evaluated. Methods for identifying mechanical complications enable preclinical screening
of stent designs, which reduces the amount of animal testing required and provides a
method for evaluating new stent designs and stenting techniques prior to animal and
human clinical trials.

In Vitro Cellular Models
Following functional and mechanical testing in a laboratory model, in vitro
cellular models are the next step in preclinical intravascular device testing. Although a
more complex dynamic system exists in vivo, a common preclinical evaluation method
involves culturing endothelial cells in vitro in order to study their response to new drugs,
materials, and devices (Cenni, et al. 1999). These cells can be maintained as twodimensional monolayers in flasks or dishes, or cultured in three-dimension adhered to
scaffolds or suspended in solution (Bokhari, et al. 2007; Cheng, Lai and Kisaalita 2008;
Cui, et al. 2007; Sun, et al. 2006). Either of these cellular models can then be exposed to
samples of new materials or medical devices in order to assess responses such as cell
proliferation, cell migration, and cell death. Although in vitro cell cultures do not reflect
the complexity of a living system, they provide important insights into cellular response
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and are critical in the effort to minimize the time and cost associated with in vivo animal
and human studies.

In Vivo Animal Models
Currently most preclinical biocompatibility and tissue response testing is done on
animals in outside laboratories, which is both time consuming and expensive. Animal
studies, however, are a valuable tool and much of what is known about restenosis and the
healing response after stent implantation has been gathered from the study of both
healthy and atherosclerotic animal models (Touchard and Schwartz 2006; Schwartz,
Chronos and Virmani 2004; Wieneke, et al. 1999).
The ideal animal model for preclinical intravascular device testing should be
readily available, inexpensive, and easy to handle. More importantly, it should closely
mimic the human pathophysiology of neointimal proliferation and remodeling (Russell
and Proctor 2006; Kantor, et al. 1999). Current animal models for preclinical
intravascular device testing include mice, rats, rabbits, pigs, dogs, and primates (Russell
and Proctor 2006; Touchard and Schwartz 2006; Schwartz, Chronos and Virmani 2004).
The Apo E-deficient mouse model has become the most widely used animal
model in atherosclerosis research (Desai, Zhao and Warren 2008; Fazio and Linton
2001). Apo E-deficient mice have been genetically altered so that they naturally develop
high cholesterol, leading to atherosclerosis and the development of coronary lesions and
blockages much like those found in human coronary arteries (Russell and Proctor 2006).
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The rat carotid artery and the rabbit iliac model are the most commonly used
animal models for testing intravascular devices targeted at preventing restenosis. Rats and
rabbits are small and relatively inexpensive, providing a fast and reliable animal model
for preclinical testing. One disadvantage is that rats and rabbits are highly resistant to the
development of atherosclerosis, necessitating the use of either a high cholesterol diet or
vessel injury to mimic coronary lesions (Schwartz, Chronos and Virmani 2004; Wieneke,
et al. 1999). However, even healthy rat and rabbit models provide important information
regarding the vascular healing response that occurs after device implantation.
In addition to rats and rabbits, the pig has become a widely used species for
assessing treatments of restenosis because its coronary anatomy and physiology are
similar to those of humans and are susceptible to atherosclerosis, developing thick
neointimal lesions in response to injury (Russell and Proctor 2006; Schwartz, Chronos
and Virmani 2004). Large animas, such as dogs and primates, are also useful models but
are not commonly used due to high cost, ethical considerations, and long life spans.
Although preclinical animal studies are accepted as a means to predict the
probability of device safety and effectiveness in humans, no animal model can provide
complete insight into the human healing response following stent implantation (Wall and
Shani 2008; Fazio and Linton 2001; Wieneke, et al. 1999). The need exists for preclinical
testing using live human cells and tissue. Preclinical testing using human cells would
greatly increase the medical community’s understanding of tissue response to a specific
device prior to animal and patient testing and prior to device release. Presently, it is
difficult to simulate device and tissue interaction and research still needs to be done to
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fully understand tissue behavior and the in vivo interaction that occurs between device
and tissue.

Blood Vessel Mimic
Previous work has demonstrated that a 3-dimensional in vitro tissue engineered
blood vessel mimic (BVM) can be created and maintained in a bioreactor system to serve
as a potentially ideal environment for coronary stent implantation and testing prior to
animal and clinical studies (Cardinal, et al. 2006). The in vitro blood vessel mimic system
can allow initial preclinical testing to be performed on a large number of coating
combinations and stent configurations in order to direct animal and clinical studies
toward the most promising devices. The major advantage of the in vitro blood vessel
mimic system is its potential for consistent high-throughput evaluation of cellular
response to advancing intravascular technologies.
The in vitro blood vessel mimic design and concept is based upon existing
techniques for tissue engineered vascular grafts and bioreactor systems. Human
microvascular endothelial cells isolated from adipose tissue are pressure sodded onto
tubular expanded polytetrafluoroethylene (ePTFE) scaffolds and cultivated in bioreactor
systems under flow to form a “blood vessel mimic”. Results demonstrate that a thin,
confluent cellular lining on the inner lumen of the ePTFE scaffold can be created in vitro.
Stent deployment within the blood vessel mimic is also possible and after being
cultivated in the bioreactor system for several days a thin lining of cells forms over the
stent surface.
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The BVM system described above (Cardinal, et al. 2006) consists of a custom
built horizontal rectangular vessel chamber that houses an ePTFE scaffold. An individual
BVM chamber is shown below in Figure 1.12. Following vessel cultivation and growth
within the chamber, stents or other intravascular technologies can be evaluated and
tested.

Figure 1.12- Individual BVM chamber.

The BVM system provides an intermediate testing environment for assessing
human cellular responses to intravascular stents in a manner that combines the
advantages of both in vitro and in vivo approaches. The blood vessel mimic system
utilizes human cells, which provide the potential for more predictive preclinical results
than animal models alone can provide. It is important to note that the blood vessel mimic
system is not a substitute or replacement for animal models. The overall goal of the BVM
system is to provide a more relevant in vitro tissue model that can be used for the
preclinical evaluation of new intravascular devices.
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Summary and Aims of the Thesis
Coronary artery disease affects millions of people and the ability to detect and
treat the disease is advancing at a rapid rate. Intravascular device technology is the focus
of many medical device manufacturers and with coronary stent implantation being
performed in an increasing number of patients a number of new stent designs have been
introduced to the market, resulting in the need for improved preclinical testing methods.
A blood vessel mimic (BVM) system has previously been established and its
feasibility for the initial testing of newly emerging intravascular technology has been
demonstrated. The current BVM system has been used successfully to support the growth
of tissue engineered in vitro blood vessel mimics, and its components and usefulness
have been summarized. With that said, there are limitations that exist with the original
design and the focus of this thesis is to both improve and expand upon the original model.
The goal of this thesis is to develop a BVM system which has the advantages of
simplicity and ease of assembly, as well as the ability to accommodate varying sizes of
vessel scaffolds and to expand the BVM concept to an area that currently has not been
addressed, such as long, angulated and bifurcation lesions, all while maintaining the
needs of a tissue engineering bioreactor system.
The general hypothesis driving this thesis project was that design changes could
be made and new configurations implemented to the BVM system that would improve
function and usability for preclinical device testing. In order to test this hypothesis,
research was conducted based on two specific aims. The first aim was to develop a more
ideal BVM system. The specific hypothesis in this case was that a BVM chamber could
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be created to accommodate a wider range of stent lengths and diameters, while allowing
for easy graft insertion and seal-ability. The second aim was to develop next generation
BVM systems, focused on future needs and technology. The hypothesis in this case was
that with emerging technology the ability to test stents specifically for bifurcation lesions,
as well as in long and angulated vessels, will be needed and is possible within the BVM
system. The prototypes developed and the findings from constructed models are
presented and discussed in the following chapters.
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2. INITIAL DESIGN OF AN IDEAL BVM
Introduction
A bioreactor is a system in which conditions are closely controlled in order to
induce a specific behavior in living cells or tissue (Martin, Wendt and Heberer 2004;
Korossis, et al. 2005). Design and construction of bioreactors are very important in tissue
engineering research, because they directly provide the in vitro environment for tissue
growth (Chen and Hu 2006). A bioreactor attempts to mimic physiological conditions in
order to maintain and encourage cell growth. Bioreactor technologies intended for tissue
engineering can be used to grow functional cells and tissues for transplantation and for
controlled in vitro studies. It is the second application on which this thesis is focused: the
use of bioreactors for controlled in vitro studies.
The primary objectives of tissue engineering bioreactors are to establish spatially
uniform cell distributions on three dimensional scaffolds, to maintain desired
concentrations of gases and nutrients in the culture medium, and to expose developing
tissue to appropriate physical stimuli (Korossis, et al. 2005). The requirements of a
bioreactor vary depending on the dimensions, complexity, and physiological environment
of the tissue to be engineered. Most importantly, however, the bioreactor has to be able to
operate over sustained periods of time under aseptic conditions so that cells are able to
grow and function (Chen and Hu 2006). The overall goal is to create a system that
reliably and reproducibly supports the growth of functional living tissue (Martin, Wendt
and Heberer 2004; Ratcliffe and Niklason 2002).
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The previously developed, original BVM system (Cardinal, et al. 2006) consists
of a custom built horizontal rectangular vessel chamber with three ports: a luminal inlet,
luminal outlet, and extra luminal outlet. Both outlets lead to a two-port media reservoir,
with external side clamps controlling the flow path. The scaffold is attached to two
barbed fittings which are inserted into the luminal inlet and luminal outlet ports located
within the vessel chamber. Adjustments to length are made by pulling or pushing the
tubing in or out of the chamber. The top of the chamber is optically clear allowing for
easy visualization of the scaffold, media and stent placement. The chamber itself is sealed
using rubber o-rings and clamped together by tightening four screws. Flow is created
using a peristaltic pump, with media entering the luminal inlet and exiting through the
luminal outlet and extra luminal outlet. The system can be sterilized using ethylene oxide
(EO) gas. Although advantages of this original system exist, it would be desirable to
improve upon this design in order to create a more ideal BVM system.
One common disadvantage among many bioreactor systems is the amount of
difficulty experienced when installing or removing scaffolds (Singh, et al. 2007), and this
is true for the original BVM system. This is often a challenge in itself as sterility needs to
be maintained at all times. Easy handling and assembly also lowers the risk of
contamination (Fisher, Mikos and Bronzino 2007). A more user friendly design is one of
the primary needs of the BVM system. Easy scaffold insertion, without the need for
bending or twisting, along with a method to quickly and simply seal the vessel chamber
without the need for tools, would greatly improve the usability of the BVM system.
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A second need for the BVM system is the ability to accommodate a wider range
of stent sizes. As discussed in detail in the introduction to this thesis, stents range in
shape and size, and thus a BVM system would ideally accommodate 2.0-5.0 mm
diameters and 8-38 mm lengths (Kandzari, Tcheng and Zidar 2002; Kraitzer, Kloog and
Zilberman 2008), in order to fit the variations of coronary arteries observed in clinical
practice and the stents currently available in the market.
In addition, ideally the BVM system would be easy to manufacture and utilize
materials and components that are readily available and cost-effective so that scale-up is
possible (Fisher, Mikos and Bronzino 2007; Martin, Wendt and Heberer 2004). Other
considerations in design of the BVM system include sterilization method, incubator
configuration, aseptic change of culture media, tissue monitoring, and reproducibility
(Fisher, Mikos and Bronzino 2007). The aim of the work in this chapter was to improve
upon the original BVM system by developing a new, more ideal design, with the
hypothesis being that a simpler, easier to use and more variable design could be created
and implemented for preclinical device testing. The specific design criteria to be met are
summarized below:


An overall user friendly design so that assembly is simple and straightforward



Easy scaffold insertion and removal without the need for bending or twisting



Easy to seal leak-proof chamber for quick and sterile assembly



Adjustable scaffold length and diameter for greater testing variability



Sterilizable by ethylene oxide (EO) gas



Optically clear chamber for easy visibility of scaffold, media and stent placement

54



Easy scale-up so that multiple chambers can be configured in the incubator



Low cost



Easy to manufacture without the need for adhesive or special tooling



Use of materials and components that are readily available and easy to obtain



Use of biocompatible materials so that cells are able to grow and function
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Initial Design Models and Concepts
Initial design ideas and concepts were drawn and modeled. These designs were
free flowing ideas based only on the known limitations, needs and design criteria to be
met for the new BVM system. Ideas were recorded or drawn in a lab notebook over a
time period of several days before any evaluations were made. Drawings were then
turned into basic 3D models using SolidWorks (SolidWorks Student Design Kit 2008) for
visualization and comparison. These designs were recorded without regard to feasibility
of design, availability of components, cost or any other idea limiting factors. It should be
noted that only the luminal inlet and luminal outlet were modeled, since location of the
extra luminal outlet was not critical to the basic design. In addition, tubing attachment,
connections and fittings were not addressed in these initial designs as the goal was only
to develop a basic model. The five initial design ideas that were developed are modeled
and described below.
Prior to the building of any prototypes the initial design ideas and concepts were
reviewed and evaluated based on the following criteria: user friendly design, seal-ability,
availability of materials and components, adjustability, and overall cost. Each model was
examined to first determine if it could actually be built and function, and if so, whether
the components were readily available or easy to create. Finally, even if the design could
be built and parts were available, consideration was taken into design complexity,
manufacturability and overall cost. The evaluation of each initial design is presented
below following the design model and description.
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Initial Design 1
Description: The first initial design idea consisted of clear plastic rectangular top
and bottom sections that meet at the center and snap together. The two sections could be
separate pieces or possibly held together by a hinge. The entire midsection would contain
a rubber o-ring and when snapped together the top and bottom sections would create a
leak-proof seal. Two centered holes would be made on opposite ends of the box, resulting
in half circle indentations on both the top and bottom sections. The two holes on either
end of the box would also contain a rubber seal and when snapped together they would
encompass the scaffold and tubing and create a tight leak-proof seal around the tubing.
During set-up, the scaffold and tubing would be placed along the center of the bottom
section, within the half circle indentations, prior to placement of the top section. Initial
Design 1 is modeled in Figures 2.1 and 2.2 below.

Figure 2.1- Exploded 3D model of Initial Design 1. An exploded view shows the overall
design concept with the top and bottom sections separated. The scaffold and tubing is set
across the bottom section and placed within the half circle indentations.
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Figure 2.2- Assembled 3D model of Initial Design 1. An assembled view shows the
overall design concept with the top and bottom sections snapped and sealed together. The
scaffold and tubing is encompassed between the top and bottom sections, with the half
circle indentations sealed around the tubing.

Evaluation: The biggest advantage of this design is that the snapping top and
bottom sections would be easy to assemble and use. This design would be easy to open,
close and put together. The box design would be easy to configure in an incubator and is
stackable. Scaffold placement would be simple, as it would lie across the bottom section
within the half circle indentations. The scaffold and tubing could be set in place without
the need for stretching or bending. Clear plastic would allow for visibility and could be
sterilized using ethylene oxide (EO) gas. The scaffold length would be somewhat
variable, but limited by the chamber length. The limiting factor of this design is sealability. The entire midsection must seal together and the half circle indentations must
create a leak-proof seal around the tubing. Manufacture of this type of seal design would
be complicated, expensive and require adhesive and custom made parts. The major
disadvantage of this design was that no container could be found with this configuration
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and creating a functioning seal would be challenging. The overall evaluation of Initial
Design 1 is summarized below:


User friendly design: Yes- chamber would be easy to assemble and scaffold
would be easy to insert



Seal-ability: Difficult- it would be hard to design and ensure a complete leakproof seal across the tubing and along all edges



Availability of materials and components: Custom- some components would need
to be custom built and designed



Adjustability: Limited- longest scaffold would be limited by chamber length



Cost: Moderate to High- due to custom parts and complex seal design
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Initial Design 2
Description: The second initial design idea consisted of two clear plastic
cylindrical sections that meet at the center and slide together, encompassing the scaffold
and tubing. The two sections would be separate pieces with the inside diameter of the
larger section matching the outside diameter of the smaller section. The open ends of the
cylindrical sections would contain rubber o-rings and when slid together the two sections
would create a leak-proof seal. The resulting seal would function both in a stationary
position and when the two sections are slid together or apart. Two centered holes would
be made on opposite ends of the cylinder, with the tubing and scaffold placed within the
center. During set-up, the scaffold would be inserted into the tubing, prior to closure of
the two sections. Initial Design 2 is modeled in Figures 2.3 and 2.4 below.

Figure 2.3- Exploded 3D model of Initial Design 2. An exploded view shows the overall
design concept with the two cylindrical sections separated. The scaffold and tubing is
placed within the center.
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Figure 2.4- Assembled 3D model of Initial Design 2. An assembled view shows the
overall design concept with the two cylindrical sections slid and sealed together. The
scaffold and tubing is encompassed within the two cylindrical sections.

Evaluation: The biggest advantage of this design is that the length of the chamber
would be easily adjustable. The two sliding sections would allow for variable scaffold
length with precise adjustment of chamber length depending on the scaffold size used.
The sliding cylindrical sections would be easy to assemble and scaffold placement would
be simple. Clear plastic would allow for visibility and could be sterilized using ethylene
oxide (EO) gas. Again, the overall limiting factor of this design is seal-ability. This
design would need circular o-ring seals on the cylindrical sections, and the seals would
need to hold and remain leak-proof while sliding. Manufacture of this type of seal design
would be complicated, expensive and most likely wear out over time due to sliding. This
design would be difficult to build even though the materials are available. Usability is
also a concern. A cylindrical shape would be challenging to work with and place in the
incubator as it would roll and is not stackable. This design would also be difficult to
configure in regards to tubing adjustability, as the tubing would also need to slide and
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adjust as the chamber slides. The overall evaluation of Initial Design 2 is summarized
below:


User friendly design: Somewhat- chamber would be easy to assemble and
scaffold would be easy to insert, but chamber would roll on a flat surface



Seal-ability: Difficult- it would be hard to design and ensure a complete leakproof sliding seal that would not wear over time



Availability of materials and components: Custom- some components would need
to be custom built and designed



Adjustability: High- chamber length can be easily adjusted to scaffold length



Cost: Moderate to High- due to custom parts and complex seal design
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Initial Design 3
Description: The third initial design idea consisted of a clear plastic cylindrical
center section with clear plastic adjustable corrugated tubing on both ends. The
corrugated tubing sections could be pushed and pulled to change the overall length of the
chamber. The corrugated tubing would be permanently attached and sealed to the center
section with one end completely closed. The other end of the corrugated tubing would
have a threaded or snapping leak-proof cap to create an opening for scaffold placement.
Two centered holes would be made, one on the closed end of the cylinder and one on the
cap, and the tubing and scaffold would be placed through the center. During set-up, the
scaffold would be inserted into the tubing, prior to closure of the cap. Initial Design 3 is
modeled in Figures 2.5 and 2.6 below.

Figure 2.5- Side view 3D model of Initial Design 3. A side view shows the overall design
concept with the corrugated tubing sections attached to the center section. The scaffold
and tubing is placed within the center.
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Figure 2.6- Assembled 3D model of Initial Design 3. An assembled view shows the
overall design concept with the corrugated tubing sections and center sealed together.
The scaffold and tubing is encompassed within the chamber.

Evaluation: The biggest advantage of this design is that the length of the chamber
would be easily adjustable. The corrugated tubing could be pushed and pulled and would
allow for variable scaffold length with precise adjustment of chamber length depending
on the scaffold size used. The snapping cap would be easy to assemble and seal. Clear
plastic would allow for visibility and could be sterilized using ethylene oxide (EO) gas.
Scaffold insertion would be difficult, since access to the center can only be made from
one end. Manufacture of this type of design would be difficult requiring adhesive when
attaching the corrugated tubing to the center section. In addition, corrugated tubing is
expensive and custom lengths and configurations would be needed. The limiting factors
for this design are scaffold insertion, manufacturability and cost. Again, usability is a
concern. A cylindrical shape would be challenging to work with and place in the
incubator as it would roll and is not stackable. This design would be difficult to configure
in regards to tubing adjustability, as the tubing would need to slide and adjust as the
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corrugated tubing is pulled or pushed. The overall evaluation of Initial Design 3 is
summarized below:


User friendly design: No- chamber would be easy to assemble but scaffold
insertion would be difficult and chamber would roll when on a flat surface



Seal-ability: Easy- entire chamber would be closed and only need a leak-proof
sealing cap



Availability of materials and components: Custom- corrugated tubing would need
to be custom ordered and designed



Adjustability: High- chamber length can be easily adjusted to scaffold length



Cost: High- due to corrugated tubing, adhesive, manufacturing and overall
complex and custom design
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Initial Design 4
Description: The fourth initial design idea consisted of a clear plastic rectangular
box with snap-on sealing lid. The box and lid could be separate pieces or possibly held
together by a hinge. The box would be completely open on top, allowing for complete
access into the chamber, and the lid would contain a rubber o-ring. When snapped
together the lid would create a leak-proof seal against the top of the box. Two centered
holes would be made on opposite sides in the bottom of the box, and the tubing and
scaffold would be positioned in the middle. During set-up, the scaffold and tubing would
be placed in the center of the bottom section, prior to placement and closure of the lid.
Initial Design 4 is modeled in Figures 2.7 and 2.8 below.

Figure 2.7- Exploded 3D model of Initial Design 4. An exploded view shows the overall
design concept with the top and bottom sections separated. The scaffold and tubing is
placed in the center of the bottom section.
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Figure 2.8- Assembled 3D model of Initial Design 4. An assembled view shows the
overall design concept with the top and bottom sections snapped and sealed together. The
scaffold and tubing is encompassed within the box.

Evaluation: The biggest advantage of this design is that the snapping lid would be
easy to assemble, use and seal. This design would be easy to open, close and put together.
The box design would be easy to configure in an incubator and is stackable. Scaffold
placement would be simple, as it would be placed in the center of the bottom section.
Clear plastic would allow for visibility and could be sterilized using ethylene oxide (EO)
gas. Containers of this type are readily available in a number of shapes and sizes and are
low in cost. No custom designed parts would be needed and manufacturing would be
simple without the need for adhesive or any complex seal design. This design would be
easy to build and materials are available. The scaffold length would be somewhat
variable, but limited by the chamber length. The main drawback of this design is that the
length of the chamber is not easily adjustable. The overall evaluation of Initial Design 4
is summarized below:
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User friendly design: Yes- chamber would be easy to assemble and scaffold
would be easy to insert



Seal-ability: Easy- only the lid would contain a sealing o-ring which would
experience minimal wear



Availability of materials and components: Off the Shelf- standard shaped
container available in many sizes with no custom parts



Adjustability: Limited- longest scaffold would be limited by chamber length



Cost: Low- materials and components are off the shelf and readily available with
nothing custom needed
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Initial Design 5
Description: The final initial design idea consisted of a clear plastic cylindrical
container with sealing snap-on lid. The cylindrical container would be open on top and
the lid would contain a rubber o-ring seal. When snapped together the lid would create a
leak-proof seal against the top of the cylindrical container. Two holes would be made in
the lid. The tubing and scaffold would hang vertically from one of the holes, loop around
in a u-shape, and exit through the second hole. Initial Design 5 is modeled in Figures 2.9
and 2.10 below.

Figure 2.9- Exploded 3D model of Initial Design 5. An exploded view shows the overall
design concept with the top and bottom sections separated. The scaffold and tubing are
looped into a u-shape and hang vertically from the lid.
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Figure 2.10- Assembled 3D model of Initial Design 5. An assembled view shows the
overall design concept with the top and bottom sections snapped and sealed together. The
scaffold and tubing are encompassed within the cylindrical chamber.

Evaluation: The biggest advantage of this design is that the snapping lid would be
easy to assemble, use and seal. Scaffold placement would be simple, as it would hang
from the lid. Clear plastic would allow for visibility and could be sterilized using
ethylene oxide (EO) gas. The chamber would be easy to configure in an incubator but is
not stackable due to the tubing being attached to the lid. Containers of this type are
readily available in a number of shapes and sizes and are low in cost. No custom
designed parts would be needed and manufacturing would be simple without the need for
adhesive or any complex seal design. This design would be easy to build and materials
are available. The scaffold length would be somewhat variable, but limited by the
container length. In addition, the tubing length would need to be adjusted each time the
scaffold length is changed. The key difference and possible challenge in this design is
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that the scaffold is oriented vertically. The overall evaluation of Initial Design 5 is
summarized below:


User friendly design: Yes- chamber would be easy to assemble and scaffold
would be easy to insert



Seal-ability: Easy- only the lid would contain a sealing o-ring which would
experience minimal wear



Availability of materials and components: Off the Shelf- standard shaped
container available in many sizes with no custom parts



Adjustability: Limited- longest scaffold would be limited by chamber length



Cost: Low- materials and components are off the shelf and readily available with
nothing custom needed
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Evaluation of Initial Design Models and Concepts
A summary of the design criteria evaluated in the previous section is given in
Table 2.1 below. Initial designs 1 through 5 were evaluated based on user friendly design,
seal-ability, availability of materials and components, adjustability, and overall cost. The
results of these evaluated criteria were used when deciding what initial designs to move
forward with and build into physical prototypes.

User Friendly
Design
Seal-Ability
Availability of
Materials and
Components
Adjustability
Cost

Initial
Design 1

Initial
Design 2

Initial
Initial
Initial
Design 3 Design 4 Design 5

Yes

Somewhat

No

Yes

Yes

Difficult

Difficult

Easy

Easy

Easy

Custom

Custom

Very
Custom

Off the
Shelf

Off the
Shelf

Limited
Moderate
to High

High
Moderate
to High

High

Limited

Limited

High

Low

Low

Table 2.1- Evaluation of initial design ideas. The initial design ideas were evaluated
based on the following criteria: user friendly design, seal-ability, availability of materials
and components, adjustability, and overall cost.

Ultimately the final decision on what designs to move forward with and build into
prototypes was based on seal-ability and availability of materials and components, along
with consideration of the other above stated criteria. The highest priority was choosing a
design that could be easily sealed and remain leak-proof, so that sterility could be
maintained. Seal-ability is extremely important since a sterile environment is needed for
cell and tissue growth (Fisher, Mikos and Bronzino 2007; Chen and Hu 2006). The next
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consideration was choosing a design that could actually be built, utilizing materials and
components that are readily available, since the aim of this thesis was to both design and
build a BVM system for preclinical device testing. A design was needed that could be
easily manufactured without the need for adhesive or custom parts. A more user friendly
design was one of the primary needs of the BVM system and was the next consideration.
Those designs in which scaffold placement was simple and overall usability was easy
were given priority. Although cost was not a major deciding factor, the designs that
utilized off the shelf components also had the advantage of being low cost. Finally, a
more variable design with the ability to accommodate a wider range of stent sizes was the
last consideration. In evaluating all the designs, adjustability became a minor
consideration. Although a custom adjustable chamber would be nice, a longer scaffold
could be easily accommodated in the other designs by simply choosing a larger container.
Therefore, adjustability was given the least priority when choosing the designs with
which to move forward and prototype. To summarize, the evaluated design criteria were
given the following priorities:
1. Seal-ability
2. Availability of materials and components
3. User friendly design
4. Cost
5. Adjustability
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After prioritizing the above criteria and evaluating the results found in Table 2.1,
only initial designs 3, 4 and 5 met the top design criteria of being easy to seal.
Additionally, initial designs 4 and 5 met the second criteria utilizing materials and
components that are easily available and off the shelf, rather than needing to be custom
designed or ordered. Early evaluation revealed initial designs 4 and 5 as the designs with
the most potential, meeting the top 4 out of 5 design criteria stated above.
While searching for available materials and components, a simple solution was
found to overcome the challenge of seal-ability and manufacturability which further
narrowed the overall design considerations down to initial designs 4 and 5. By using a
leak-proof plastic food container with snap-on sealable lid and built in o-ring, the basic
chamber design was solidified and initial designs 4 and 5 were chosen to be prototyped.
Initial designs 4 and 5 also had the advantage of being both user friendly and low cost
designs. Figure 2.11 below shows commercially available plastic food containers with
snap-on lids in several different shapes and sizes.

Figure 2.11- Leak-proof plastic food container with snap-on sealing lid.

74

A leak-proof plastic food container was chosen for the chamber design because it
is easy to seal, made of clear biocompatible and sterilizable plastic, low cost and
available in local stores. Leak-proof polypropylene food containers come in a variety of
shapes, sizes and configurations with lids that have built-in silicone o-rings. The leakproof food container meets the following design criteria stated in the introduction:
 An overall user friendly design so that assembly is simple and straightforward


Standard container configuration with snap-on lid

 Easy to seal leak-proof chamber for quick and sterile assembly


Lid has built-in silicone o-ring and latches that snap to seal

 Sterilizable by ethylene oxide (EO) gas


Polypropylene and silicone can withstand EO sterilization

 Optically clear chamber for easy visibility of scaffold, media and stent placement


All sides of container are see-through

 Easy scale-up so that multiple chambers can be configured in the incubator


Containers are stackable and modular

 Low cost


Approximately $3-10 per container, depending on size

 Made of materials and components that are readily available and easy to obtain


Containers can be purchased in local stores or online

 Made of biocompatible materials so that cells are able to grow and function


Polypropylene and silicone are biocompatible materials
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Design Prototypes
After identifying containers and identifying initial designs 4 and 5 as the best
potential candidates, the next step was to build physical prototypes to evaluate and further
narrow the selection to one final design. The following two prototypes were constructed
by purchasing leak-proof plastic food containers from Linens-N-Things, fittings and
connections from Value Plastics, Qosina, and McMaster-Carr and flexible tubing from
Cole-Parmer. The two prototypes were assembled based on the above models of initial
designs 4 and 5 and are shown and described below. Details on how the fittings were
secured, specific parts used and the entire assembly process will be addressed in the
following chapter after the final design has been chosen. The goal of this section was to
build physical prototypes that could be held, compared, and evaluated by potential users
in order to determine the final design.

Design Prototype 1
Description: The first prototype built was based on the model of initial design 4.
A rectangular, clear, plastic, leak-proof food container with snap-on sealing lid was used
for the chamber. The container used measured approximately 5" long x 3.5" wide x 2"
deep. The lid contained a silicone o-ring seal and four snapping latches that locked to the
bottom section securing the bottom and lid together. Two holes were made on opposite
sides of the container and threaded luer lock to barbed connection fittings were secured
within the holes. The scaffold was horizontally positioned between the fittings using the
appropriate connections. Adjustment to scaffold length could be made by adding or
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removing fittings. Photographs of the physical prototype built are shown below in
Figures 2.12 and 2.13.

Figure 2.12- Side view of Prototype 1. A rectangular plastic leak-proof container with
snap-on sealing lid was used for the chamber.

Figure 2.13- Top view of Prototype 1. The scaffold was horizontally positioned within
the chamber using the appropriate connections.
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Design Prototype 2
Description: The second prototype built was based on the model of initial design
5. A tall rectangular, clear, plastic, leak-proof food container with snap-on sealing lid was
used. The container used measured approximately 4" wide x 4" wide x 4.5" tall. The lid
contained a silicone o-ring seal and four snapping latches that locked to the bottom
section securing the bottom and lid together. Two holes were made in the lid of the
container and threaded luer lock to barbed connection fittings were secured within the
holes. The scaffold was hung vertically from the lid using the appropriate connections
and the tubing was configured in a u-shape. Adjustment to scaffold length could be made
by changing the opposite side tubing length. A photograph of the physical prototype built
is shown below in Figure 2.14.

Figure 2.14- Front view of Prototype 2. A rectangular plastic leak-proof container with
snap-on sealing lid was used for the chamber. The scaffold hung vertically from the lid.
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Evaluation of Design Prototypes
Prototypes 1 and 2 were evaluated in comparison with the original BVM system
and to each other based on an expanded list of key criteria. The original BVM system
along with physical Prototypes 1 and 2 were handled and used by several individuals in
order to evaluate overall usability and ease of scaffold insertion. Measurable criteria
evaluated included volume, maximum scaffold length and diameter, and maximum stent
size. Observable criteria included graft orientation, closure mechanism, need for
assembly tools, and stack-ability. Other criteria included cost and chamber design. Table
2.2 below summarizes the results of the compared criteria of the original BVM system,
Prototype 1 and Prototype 2.

Overall Usability
Scaffold Insertion
Chamber Volume
Graft Orientation
Closure Mechanism
Assembly tools required
Stackable
Max Scaffold Length
Scaffold Diameters
Maximum Stent Length
Stent Diameters
Cost
Chamber Design

Original BVM
System
moderate
difficult
25 ml
horizontal
screws
yes
no
4.5 cm
3-4 mm
25 mm
3-4 mm
moderate
custom

Design
Prototype 1
easy
easy
350 ml
horizontal
locking snaps
no
yes
5.5 cm
2-6 mm
35 mm
2-6 mm
low
off the shelf

Design
Prototype 2
easy
moderate
700 ml
vertical
locking snaps
no
no
6 cm
2-6 mm
40 mm
2-6 mm
low
off the shelf

Table 2.2- Evaluation of design prototypes versus original BVM system. The design
prototypes were compared to the original BVM system and evaluated based on objective,
measurable and observable criteria.
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Prototype 1 and Prototype 2 met all design criteria stated in the introduction.
When compared to the original BVM system, both prototypes also had the advantage of
being more user friendly with easier scaffold placement and utilized a simpler closure
mechanism without the need for assembly tools. The overall usability and ease of
scaffold insertion was evaluated by the individuals that make up the 2008 BVM Lab
Group, after handling and using all three designs. It was observed that locking snaps
provided a quick and simple sealing method when compared with the previous method of
tightening screws. Also, by using rotating fittings in the prototype designs the need to
bend, push or twist the scaffold during insertion was eliminated.
In addition to usability characteristics, the prototypes were lower cost and
chamber designs were non-custom and off the shelf. Maximum scaffold length and
diameter was also greater in the prototype designs, resulting in the accommodation of a
wider range of stent sizes. The stent sizes that could be inserted into the scaffold were
estimated by taking the maximum scaffold length and subtracting 2 cm to take into
account the amount of material used for attachment and the amount of non-useable area.
As described above, Prototypes 1 and 2 have many advantages over the original
BVM system. The next step in designing a new, more ideal BVM was to compare
Prototypes 1 and 2 to each other. The significant difference in design between Prototype
1 and Prototype 2 was scaffold orientation. The original BVM system utilizes a
horizontal scaffold orientation and previous evaluation and use of a vertically oriented
scaffold have revealed difficulties in cell sodding, with the cells tending to migrate to the
bottom of the scaffold due to gravity (KO Cardinal, unpublished data). Therefore the
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biggest disadvantage of Prototype 2 was the vertical scaffold orientation. Chamber
volume was also compared and considered. Although not critical, a smaller volume is
more advantageous since it requires less media to fill. Both prototypes were much larger
in volume than the original BVM system, however, Prototype 2 was twice the volume of
Prototype 1. In addition to a horizontal scaffold orientation and smaller chamber volume,
Prototype 1 also has the advantage of being stackable when compared to Prototype 2. As
a result of these advantages, Prototype 1 was chosen to be used for the final design.

Final Design
Based upon the previously discussed evaluation, Prototype 1 was chosen to be
used as the final design. The following chapter will review in detail the design,
construction and set-up of this Ideal BVM system as well as the testing performed to
validate and verify its functionality and use.
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3. FINAL DESIGN OF IDEAL BVM
Introduction
As stated in the previous chapter, design and construction of bioreactors are
important in tissue engineering research because they directly provide the in vitro
environment for tissue growth (Chen and Hu 2006). A bioreactor must operate over
sustained periods of time under aseptic conditions so that cells are able to grow and
function. The goal is to create a system that reliably and reproducibly supports the growth
of functional living tissue (Martin, Wendt and Heberer 2004; Ratcliffe and Niklason
2002). In the case of a Blood Vessel Mimic (BVM), the goal is to create an environment
to cultivate tissue engineered blood vessels (TEBV) in order to serve as a living vessel
model for preclinical device testing (Cardinal, et al. 2006). The aim of the work in the
previous chapter was to improve upon the original BVM system by developing a new,
more ideal design. A simpler, easier to use and more variable design was selected from
several potential ideas and an initial physical prototype was built and modeled.
The new Ideal BVM system developed and prototyped in the previous chapter
consists of an off the shelf leak-proof plastic horizontal rectangular vessel chamber with a
luminal inlet, luminal outlet and extra luminal outlet. The outlets lead to a two-port media
reservoir, with stopcocks controlling the flow path. The scaffold is attached to two
rotating luer fittings which are attached to the luminal inlet and luminal outlet ports
located within the vessel chamber. Adjustments to length are made by adding or
removing luer fittings. All sides of the chamber are optically clear allowing for easy
visualization of the scaffold, media and stent placement. The chamber itself is sealed by a
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built-in silicone o-ring and clamped together by closing four snapping latches. The
system can be sterilized using ethylene oxide (EO) gas. The specific design criteria met
by the Ideal BVM were summarized in Chapter 2 and provided the motivation for
moving forward with this design. Therefore, the aim of the work in this chapter is to
describe in detail the finalized design, construction and set-up of this Ideal BVM system
and the testing performed to validate and verify its functionality and use.
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Materials and Methods
Ideal BVM System
This section outlines the steps taken to build the new Ideal BVM system. The
assembly process is described in detail and includes the specific parts used along with
detailed illustrations. While this section provides the materials and methods for
construction of the Ideal BVM system, a detailed list of parts and drawings, as well as
complete step-by-step directions can also be found in Appendix B and C respectively.
The new, Ideal BVM system was constructed as follows.
To begin, the luminal inlet, luminal outlet and extra luminal outlet were created
and assembled. Three 15/64" holes were drilled into the sides of a 350 ml, 5" x 4" x 2",
semitransparent, polypropylene rectangular snap and seal leak-proof food container
(Lock & Lock P/N HPL806). Two holes were drilled on opposite sides, one in the center
of each face, directly across from one another. The centered hole on the left hand side
became the luminal inlet and the centered hole on the right hand side became the luminal
outlet. A third hole was drilled adjacent to the centered face hole on the right hand side of
the container. This hole became the extra luminal outlet. Using a razor blade, the edges of
the holes were cleaned of any plastic debris that resulted from the use of the drill. A soft
black Buna-N o-ring, AS568A dash number 006, durometer 50A, 1/4" OD, 1/8" ID,
1/16" W (McMaster-Carr P/N 2418T112) was slid onto a white nylon, female luer lug
style panel mount connector, 1/4-28 UNF to 200 series barb, 1/8" ID tubing (Value
Plastics P/N FTLB230-1) and threaded through one of the drilled holes with the barbed
portion exiting the container. A second o-ring was placed over the barbed section and a
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white nylon, 1/4-28 UNF panel mount lock nut (Value Plastics P/N LNS-1) was screwed
on tightly, pressing the o-rings against the inside and outside of the container walls,
creating a leak-proof seal. Once securely tightened, a drop of Loctite 4011 medical grade
adhesive (McMaster-Carr P/N 1818A4) was placed between the lock nut and the threaded
portion of the barbed fitting to secure it in place and prevent loosening. This procedure
was repeated for the remaining drilled holes. Figures 3.1 and 3.2 below illustrate this
assembly procedure.

Female
Luer Lug
Panel Mount

O-Rings

Lock Nut

Figure 3.1- Assembly of the luminal inlet and luminal outlets. Each of the three 15/64"
holes was assembled using two o-rings, a female luer lug panel mount and a lock nut.
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Luminal
Inlet

Extra Luminal
Outlet
Luminal
Outlet

Figure 3.2- Completed assembly of the luminal inlet and luminal outlets. The female luer
lug panel mounts were threaded through the holes drilled in the plastic container and the
lock nuts were tightened, pressing the o-rings against the container walls creating a seal.

To complete the luminal inlet assembly a 2" piece of Tygon® silicone tubing,
1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) was inserted onto the barbed fitting
of the luminal inlet exiting the left side of the container. A white nylon, female luer
thread style to 200 series barb, 1/8" ID tubing (Value Plastics P/N FTLL230-1) was
attached to the open end of the silicone tubing attached to the luminal inlet. Finally, a
three-way polycarbonate stopcock with two female and one male luer lock ends (Value
Plastics P/N VPB1000079N) was attached to the female luer end on the luminal inlet
tubing. The assembly process described is illustrated in Figures 3.3 and 3.4 below.
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Three-Way
Stopcock
Female Luer
Thread Barbed
Fitting

Silicone Tube

Figure 3.3- Luminal inlet tubing assembly. The luminal inlet consists of a short piece of
silicone tubing, a female luer thread barbed fitting, and a three-way stopcock.

Figure 3.4- Completed luminal inlet tubing assembly.
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To complete the luminal outlet and extra luminal outlet assembly a 1" piece of
Tygon® silicone tubing, 1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) was
inserted onto the barbed fitting of the luminal outlet and a 5" piece of the same silicone
tubing was inserted onto the barbed fitting of the extra luminal outlet, both exiting the
right side of the container. A white nylon, male luer integral lock ring to 200 series barb,
1/8" ID tubing (Value Plastics P/N MTLL230-1) was attached to the open end of the
silicone tubing attached to the luminal outlet. A one-way polycarbonate stopcock with
one female and one male luer lock end (Value Plastics P/N VP455980) was attached to
the male luer end on the luminal outlet tubing. A white nylon, female luer thread style to
200 series barb, 1/8" ID tubing (Value Plastics P/N FTLL230-1) was attached to the male
end of the one-way stopcock, and a 2" piece of Tygon® silicone tubing, 1/8" ID x 1/4"
OD (Cole-Parmer P/N WU-95702-06) was inserted onto the barbed fitting of the female
luer attached to the one-way stopcock.
Next, the open ends of the silicone tubing attached to the luminal outlet and extra
luminal outlet were attached to a white nylon, Y-connector with 200 series barbs, 1/8" ID
tubing (Value Plastics P/N Y230-1). The attachment of the luminal outlet and extra
luminal outlet tubing to the Y-connector created one main outlet. Finally, a 1" piece of
Tygon® silicone tubing, 1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) was
inserted onto the barbed fitting of the Y-connector and a white nylon, male luer integral
lock ring to 200 series barb, 1/8" ID tubing (Value Plastics P/N MTLL230-1) was
inserted into the open end of the silicone tubing attached to the Y-connector. A one-way
polycarbonate stopcock with one female and one male luer lock end (Value Plastics P/N
VP455980) was attached to the male luer end on the Y-connector tubing. Figure 3.5
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provides an overall view of the assembly process, and Figures 3.6 and 3.7 provide a
closer view of the luminal outlet and extra luminal outlet assembly.

Figure 3.5- Overall view of luminal outlet and extra luminal outlet assembly.

Male Luer
Lock Barbed
Fitting

Silicone
Tube

Y-Connector
Female Luer
Thread Barbed
Fitting

One-Way
Stopcock

Figure 3.6- Detailed view of luminal outlet and extra luminal outlet assembly. The
luminal outlet assembly consists of a one-way stopcock, while the extra luminal outlet is
a simple tube. The luminal outlet and extra luminal outlet are both attached to a Yconnector and meet to form one outlet ending with a one-way stopcock.
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Figure 3.7- Completed luminal outlet and extra luminal outlet assembly. The two outlets
meet at the Y-connector combining to form one main outlet.

To complete the inside of the chamber, two male-to-male luer lock connectors,
with one rotating collar (Qosina P/N 17644), were attached to the female luer lock
connector ends of the luminal inlet and luminal outlet, extending into the chamber. The
male-to-male connectors were attached so that the rotating collars extended into the
chamber and were free to rotate. Figures 3.8 and 3.9 below illustrate this assembly
procedure. To shorten the distance between the two ends of the male-to-male luer lock
connectors, white nylon male luer integral lock ring to female luer thread style couplers
(Value Plastics P/N LC34-1) can be attached prior to the attachment of the male-to-male
luer lock connectors. The attachment of one coupler to both the luminal inlet and luminal
outlet is illustrated in Figures 3.10 and 3.11 below and will be detailed in a later section.
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Male-to-Male
Luer Lock
Connector

Figure 3.8- Attachment of male-to-male luer lock connectors. Male-to-male luer lock
connectors, with one rotating collar, were attached to the female luer lock connector end
of the luminal inlet and luminal outlet.

Rotating
End

Figure 3.9- Completed attachment of male-to-male luer lock connectors. Male-to-male
luer lock connectors were attached so that the end extending into the chamber remained
free to rotate.
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Male-to-Female
Luer Lock
Couplers

Figure 3.10- Addition of male-to-female luer lock couplers. Prior to the attachment of the
male-to-male luer lock connectors, male-to-female couplers can be added to shorten the
distance between the rotating ends.

Rotating
End

Figure 3.11- Attachment of male-to-female luer lock couplers. Male-to-male luer lock
connectors were attached so that the end extending into the chamber remained free to
rotate.
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The final complete new Ideal BVM system, prior to scaffold insertion, is
diagramed below in Figure 3.12. The lid is attached by closing four snapping latches and
a built-in o-ring creates a leak-proof seal. The Ideal BVM system was part of the overall
bioreactor configuration, which will be diagramed in a later section.

Figure 3.12- Final complete new Ideal BVM system.
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Two-Port Media Reservoir
This section outlines the steps taken to build the two-port media reservoir for the
new Ideal BVM system. After construction of the luminal inlet and luminal outlets of the
Ideal BVM system it was observed that this configuration would also improve the
function and use of the inlet and outlet ports on the media reservoir lid, allowing reservoir
construction to be accomplished without the need for a large amount of adhesive.
Therefore, the same basic construction used to build the Ideal BVM system luminal inlet
and luminal outlets was applied to the two-port media reservoir. The assembly process is
described in detail and includes the specific parts used along with detailed illustrations.
While this section provides the materials and methods for construction of the two-port
media reservoir, a detailed list of parts and drawings, as well as complete step-by-step
directions can also be found in Appendix B and D respectively.
The two-port media reservoir for the Ideal BVM system was created as follows.
Two 15/64" holes were drilled into the lid of a BD Falcon™ 50 ml conical-bottom
polypropylene tube (BD Biosciences P/N 352098). Using a razor blade, the edges of the
holes were cleaned of any plastic debris that resulted from the use of the drill. Using the
same technique described previously, a soft black Buna-N o-ring, AS568A dash number
006, durometer 50A, 1/4" OD, 1/8" ID, 1/16" W (McMaster-Carr P/N 2418T112) was
slid onto a white nylon, female luer lug style panel mount connector, 1/4-28 UNF to 200
series barb, 1/8" ID tubing (Value Plastics P/N FTLB230-1) and threaded through one of
the drilled holes with the barbed portion exiting the top of the lid. A second o-ring was
placed over the barbed section and a white nylon, 1/4-28 UNF panel mount lock nut
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(Value Plastics P/N LNS-1) was screwed on tightly, pressing the o-rings against the top
and bottom of the lid, creating a leak-proof seal. Once securely tightened, a drop of
Loctite 4011 medical grade adhesive (McMaster-Carr P/N 1818A4) was placed between
the lock nut and the threaded portion of the barbed fitting to secure it in place and prevent
loosening. This procedure was repeated for the second drilled hole. Next, a 1" piece of
Tygon® silicone tubing, 1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) was
attached to a white nylon, male luer integral lock ring to 200 series barb, 1/8" ID tubing
(Value Plastics P/N MTLL230-1) and secured to one of the female luer fittings extending
from the bottom of the lid. This port, with the attached tubing, became the outlet. The
assembly process described is illustrated in Figures 3.13 and 3.14 below.

Lock Nut
Two-Port Media
Reservoir Lid

O-Rings

Female
Luer Lug
Panel Mount
Male Luer Lock
Barbed Fitting

Silicone Tube

Figure 3.13- Assembly of two-port media reservoir lid. Each of the two 15/64" holes was
assembled using two o-rings, a female luer lug panel mount and a lock nut. A short piece
of tubing was inserted onto a male luer lock barbed fitting and attached to the assembly.
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Inlet

Outlet

Figure 3.14- Assembled two-port media reservoir. The female luer lug panel mounts were
threaded through the drilled holes and the lock nuts were tightened, pressing the o-rings
against the top and bottom of the lid, creating a seal. A short piece of silicone tubing was
attached and became the outlet.

To complete the two-port media reservoir two 10" pieces of Tygon® silicone
tubing, 1/8" ID x 1/4" OD (Cole-Parmer P/N WU-95702-06) were inserted onto the
barbed fittings of the inlet and outlet exiting the media reservoir lid. A white nylon, male
luer integral lock ring to 200 series barb, 1/8" ID tubing (Value Plastics P/N MTLL2301) was attached to the open end of the silicone tubing attached to the outlet. Likewise, a
white nylon, female luer thread style to 200 series barb, 1/8" ID tubing (Value Plastics
P/N FTLL230-1) was attached to the open end of the silicone tubing attached to the inlet.
Figures 3.15 and 3.16 below illustrate this assembly procedure. The two-port media
reservoir was part of the overall bioreactor configuration, which will be diagramed in a
later section.

96

Female Luer Thread
Barbed Fitting

Male Luer Lock
Barbed Fitting

Inlet

Outlet

Figure 3.15- Inlet and outlet tubing assembly of two-port media reservoir. A male luer
lock barbed fitting is attached to the outlet and a female luer thread barbed fitting is
attached to the inlet.

Figure 3.16- Final completed assembly of two-port media reservoir.
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Scaffold Setup and Insertion
The scaffold for the new Ideal BVM system was setup as follows. Expanded
polytetrafluoroethylene (ePTFE), 3 mm and 4 mm inner diameter (Impra Bard, Inc.,
Tempe, AZ), was used as the scaffold material. Two white nylon, female luer thread style
to 200 series barb fittings were inserted into the open ends of the ePTFE scaffold. White
nylon, female luer thread style to 200 series barb, 1/8" ID tubing (Value Plastics P/N
FTLL230-1) were used for the 4 mm inner diameter scaffolds and white nylon, female
luer thread style to 200 series barb, 3/32" ID tubing (Value Plastics P/N FTLL220-1)
were used for the 3 mm inner diameter scaffolds. The ends of the scaffold were sutured
onto the barbed ends of the female luer thread fittings using 2.0 Sofsilk™ suture material.
Figures 3.17 and 3.18 below illustrate this procedure. Depending on the number of male
luer integral lock ring to female luer thread style couplers used between male-to-male
rotating fittings, scaffolds were cut into either 5.5 cm, 4.5 cm or 3.5 cm lengths,
corresponding to 0, 1, or 2 couplers respectively. See Table 3.1 below or Appendix E for
a summary of scaffold length versus number of couplers used.

Female Luer
Thread Barbed
Fitting

ePTFE
Scaffold

Figure 3.17- Scaffold assembly. Two female luer thread barbed fittings were inserted into
the open ends of the ePTFE scaffold.
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Suture

Figure 3.18- Completed scaffold assembly. The ends of the ePTFE scaffold were sutured
to the two female luer thread barbed fittings.

Illustration

# of Couplers

Scaffold Length

0

5.5 cm

1

4.5 cm

2

3.5 cm

Table 3.1- Scaffold length versus number of couplers used.
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To secure the scaffold inside the Ideal BVM system, the female luer thread
fittings attached to the scaffold were inserted into the male-to-male luer lock fittings
attached to the luminal inlet and luminal outlet. The rotating collars of the male-to-male
luer lock fittings were tightened around the female luer thread fittings attached to the
scaffold. The inserted scaffold is illustrated below in Figure 3.19.

Scaffold
Assembly
Rotating
Male Collar

Figure 3.19- Scaffold insertion. The scaffold is secured inside the BVM system by
tightening the rotating collars of the male-to-male luer lock fittings around the female
luer thread fittings attached to the scaffold.

Bioreactor Configuration
The complete bioreactor configuration consisted of the Ideal BVM system and
two-port media reservoir connected in series. To construct the bioreactor system the male
luer lock fitting attached to the two-port media reservoir outlet tubing was secured to the
female luer thread fitting of the three-way stopcock attached to the luminal inlet of the
Ideal BVM system. Next, the female luer thread fitting attached to the two-port media
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reservoir inlet tubing was secured to the male luer lock fitting of the one-way stopcock
attached to the main luminal outlet of the Ideal BVM system. This completed the Ideal
BVM system bioreactor assembly. The Ideal BVM bioreactor system is illustrated in
Figure 3.20 below.

Figure 3.20- Ideal BVM system bioreactor configuration.

Cost Analysis
Due to the goal of creating a cost-effective, high-throughput testing environment,
the cost of each individual component and part used to create the Ideal BVM system and
two-port media reservoir was determined. The cost of all components and parts were
summed and the total cost per individual completed Ideal BVM system and two-port
media reservoir was calculated.
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Functional Verification
To verify that the Ideal BVM system and two-port media reservoir functioned
properly without leakage, a complete bioreactor configuration was setup and used. A lab
member completed a full sterile Ideal BVM setup including scaffold assembly and
insertion, media injection, and connection of the Ideal BVM and two-port media reservoir
in series. Flow through the bioreactor system was initiated by placing a section of the
two-port media outlet tubing through a peristaltic pump. The Ideal BVM functional
verification setup is illustrated in Figure 3.21 below.

Peristaltic
Pump

Figure 3.21- Ideal BVM functional verification setup. Flow was initiated by placing a
section of the two-port media outlet tubing through a peristaltic pump.
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Comparison of Ideal BVM System to Original BVM System
To compare the Ideal BVM system and the original BVM system a lab member
completed a full sterile side-by-side setup of both systems. Setup included scaffold
assembly and insertion, media injection, and connection of the BVM systems and twoport media reservoirs in series. Flow through the bioreactor systems was initiated by
placing a section of the two-port media outlet tubing through a peristaltic pump. The
Ideal BVM system and original BVM system were compared and user feedback was
gathered on overall usability, ease of scaffold insertion, user interface features,
connections and fittings, bioreactor assembly, seal-ability, aseptic use and setup, and
general component configuration. The user feedback survey can be found in Appendix F.

Blood Vessel Development
The Ideal BVM system was tested for its ability to cultivate an in vitro blood
vessel mimic. Following scaffold insertion and priming of the system with media, human
umbilical artery smooth muscle cells (HUASMC) were pressure sodded onto the luminal
surface of the ePTFE scaffold. The BVM system was placed in an incubator at 37 °C,
5% CO2, and connected to a peristaltic pump. The pump generated flow through the
lumen of the vessel over a time period of one day. After one day, the vessel was removed
from the chamber and fixed in Histochoice for evaluation. Cell deposition and cell
adherence to the vessel were evaluated using a scanning electron microscope. The fixed
vessel was cut in half longitudinally and images of the luminal surface were acquired to
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determine if the Ideal BVM system was capable of successfully supporting cell sodding
and cultivation.
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Results
Ideal BVM System
The Ideal BVM System was easy to assemble and build. All components were off
the shelf and readily available, resulting in a design that was repeatable and consistent.
No special tooling was needed and assembly was simple and straightforward. The leakproof snap and seal container was easy to work with and durable. Holes were drilled
cleanly with a handheld power drill and an ordinary 15/64" drill bit. By threading the
female luer lug panel mounts directly into the plastic the need for a large amount of
adhesive was eliminated. The double o-ring design created a leak-proof seal and allowed
for a clean and simple overall design. Tubing was easily attached to the barbed fittings
exiting the chamber and female luer threads allowed for easy attachment of male-to-male
rotating luer lock fittings. Male luer lock and female luer thread connectors and barbed
fittings made tubing and stopcock assembly easy. Due to the simplicity of design,
availability of components and easy assembly, it was possible to construct a large number
of identical systems. Therefore, thirty Ideal BVM systems were constructed for
immediate use. Assembled Ideal BVM systems are shown below in Figures 3.22 and
3.23.
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Figure 3.22- Ideal BVM System.

(a)

(c)

(b)

(d)

(e)

Figure 3.23- Assembled Ideal BVM systems. Tubing was attached to the barbed fittings
exiting the sides of the container (a) and male-to-male rotating fittings were attached to
the female luer thread fittings extending into the chamber (b) and (c). The sealing double
o-ring design (d) eliminated the need for a large amount of adhesive (e).
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Two-Port Media Reservoir
Two-port media reservoir lids were also easy to assemble and build. The sealing
double o-ring design eliminated the need for a large amount of adhesive and allowed for
a clean and simple overall design, while providing a functional seal. Tubing was easily
attached to the barbed fittings exiting the top of the lid and the 50 ml tube was easy to
screw onto the lid. The female luer thread fittings exiting the bottom of the lid also made
it easy to attach a short piece of tubing to create the outlet. Due to the simplicity of
design, availability of components and easy assembly, thirty two-port media reservoirs
were constructed for immediate use. Assembled two-port media reservoirs are shown
below in Figures 3.24 and 3.25.

Figure 3.24- Two-port media reservoir.
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(c)

(a)

(d)

(b)

(e)

Figure 3.25- Assembled two-port media reservoirs. The sealing double o-ring design (a)
eliminated the need for a large amount of adhesive (b). Tubing was attached to the barbed
fittings exiting the top of the lid (c) and a short piece of tubing was secured to the female
luer thread fitting exiting the bottom (d). Thirty two-port media reservoirs were
constructed for immediate use (e).

Scaffold Setup and Insertion
Scaffold setup was simple and straightforward. The female luer thread barbed
fittings were easy to insert into the ePTFE scaffold and the Sofsilk™ suture material was
easy to tie and successfully secured the scaffold in place. The female luer thread barbed
fittings were also easy to insert into the male-to-male rotating fittings within the Ideal
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BVM chamber. The rotating collars of the male-to-male luer lock fittings allowed
insertion to be performed without bending or twisting of the scaffold material. The
female luer thread end attached to the scaffold could be held in place while the male luer
lock rotating collar was tightened around it. These features also permitted fast and
asceptic insertion of the scaffold within the Ideal BVM chamber. Scaffold setup and
insertion are shown below in Figures 3.26 and 3.27.

Figure 3.26- Scaffold assembly.

Figure 3.27- Scaffold insertion into Ideal BVM system.
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An advantage of this new scaffold setup was that scaffold length and diameter
were easily adjustable and variations were easily accommodated within the system. By
choosing the correct size of female luer thread barbed fittings a number of diameters of
ePTFE scaffold could be used. In addition, by using Table 3.1, scaffold length was easily
adjustable by varying the number of couplers used in the inner BVM chamber assembly.
The ability to vary scaffold length and diameter allows for the accommodation a large
number of stents sizes to be tested within the Ideal BVM system.

Bioreactor Configuration
The complete bioreactor configuration, consisting of the Ideal BVM system and
two-port media reservoir connected in series, was easy to setup with the need for only
two simple connections. Specific placement of male luer lock and female luer thread
fittings ensured proper setup and orientation every time. Only one configuration existed
for setting up the bioreactor system, since the fittings of the Ideal BVM system and twoport media reservoir were designed as male-to-female connections. This new design
eliminated the confusion and complications faced in determining the correct inlet and
outlet orientation when connecting the two-port media reservoir to the Ideal BVM
system. The complete Ideal BVM bioreactor configuration is shown below in Figure
3.28.
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Figure 3.28- Complete bioreactor configuration. The Ideal BVM system and two-port
media reservoir were connected in series. Specific placement of male luer lock and
female luer thread fittings ensured proper setup and orientation every time.

Cost Analysis
The cost of each individual component and part used to create the Ideal BVM
system and two-port media reservoir and the total cost per individual completed Ideal
BVM system and two-port media reservoir is summarized in Tables 3.2 and 3.3 below.
The total cost per individual completed Ideal BVM system was $9.71 and the total cost
per individual completed two-port media reservoir was $5.54. The total cost of the
completed bioreactor configuration, including both the Ideal BVM system and two-port
media reservoir was $15.25.
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HPL806
2418T112
1818A4

Qty per
BVM
1 EA
6 EA
3 drops

Cost per
Unit
3.00
0.07
0.02

Value Plastics

FTLB230-1

3 EA

0.17

0.51

Lock Nut

Value Plastics

LNS-1

3 EA

0.08

0.24

Male Luer Lock-1/8"
Barb

Value Plastics

MTLL230-1

2 EA

0.14

0.28

Female Luer Thread1/8" Barb

Value Plastics

FTLL230-1

2 EA

0.12

0.24

Y-Connector-1/8" Barbs
Male-Female Coupler
1-Way Stopcock
3-Way Stopcock

Value Plastics
Value Plastics
Value Plastics
Value Plastics

Y230-1
LC34-1
VP455980
VPB1000079N

1 EA
2 EA
2 EA
1 EA

0.22
0.16
0.64
0.64

0.22
0.32
1.28
0.64

Male-to-Male Rotating
Luer Lock

Qosina

17664

2 EA

0.26

0.52

1/8" ID Silicone Tubing

Cole-Parmer

WU-95702-06

11 inches

0.18

1.98
$9.71

Component

Company

Part Number

Leak-Proof Chamber
Buna-N O-Ring
Loctite 4011 Adhesive

Lock & Lock
McMaster-Carr
McMaster-Carr

Female Luer Lug Panel
Mount-1/8" Barb

Total
3.00
0.42
0.06

Table 3.2- Total cost per individual completed Ideal BVM system.

Company

Part Number

Qty per
Reservoir

Cost per
Unit

Total

BD Biosciences

352098

1 EA

0.54

0.54

McMaster-Carr
McMaster-Carr

2418T112
1818A4

4 EA
2 drops

0.07
0.02

0.28
0.04

Female Luer Lug Panel
Mount-1/8" Barb

Value Plastics

FTLB230-1

2 EA

0.17

0.34

Lock Nut

Value Plastics

LNS-1

2 EA

0.08

0.16

Male Luer Lock-1/8"
Barb

Value Plastics

MTLL230-1

2 EA

0.14

0.28

Female Luer Thread1/8" Barb

Value Plastics

FTLL230-1

1 EA

0.12

0.12

1/8" ID Silicone Tubing

Cole-Parmer

WU-95702-06

21 inches

0.18

3.78
$5.54

Component
BD Falcon™ 50 ml
Tube
Buna-N O-Ring
Loctite 4011 Adhesive

Table 3.3- Total cost per individual completed two-port media reservoir.
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Functional Verification
The Ideal BVM system was used in conjunction with a two-port media reservoir
and functioned properly without any leakage. The scaffold was inserted aseptically and
the lid was easy to attach and created a leak-proof seal. The system was injected with
media which was pumped through the system via a peristaltic pump. Flow was created
through the luminal inlet and exited the luminal outlet and extra luminal outlet. The Ideal
BVM systems were EO sterilized prior to use. Photos of the Ideal BVM system being
setup and being attached to the peristaltic pump are shown below in Figures 3.29 and
3.30.

(a)

(b)

Figure 3.29- Setup of the Ideal BVM bioreactor system. The scaffold was inserted in an
aseptic manner (a) and the two-port media reservoir and Ideal BVM were connected in
series (b).
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Figure 3.30- Attachment of the Ideal BVM bioreactor system to a peristaltic pump. The
bioreactor system functioned properly without leakage.

The luminal inlet, luminal outlet and extra luminal outlet configuration permitted
variation in flow path. Transluminal and transmural flow were easily controlled via the
one-way stopcock attached to the luminal outlet. By closing off the luminal outlet path,
through the use of the one-way stopcock, transmural flow through the porous ePTFE
scaffold wall was created, with flow exiting the extra luminal outlet. Transmural flow
was used for conditioning and cell sodding of the scaffold material. By opening the oneway stopcock, transluminal flow was restored through the luminal outlet. The one-way
stopcock was easy to use and provided a quick and simple method for controlling the
flow path. The lever was easy to turn and once in position flow was immediately and
firmly blocked. The merging of the luminal outlet and extra luminal outlet into one main
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outlet via the Y-connector made attachment to the two-port media reservoir simple with
the need for only one connection. The three-way stopcock attached to the luminal inlet
easily functioned as both a flow path and cell sodding port. With two female luer thread
fittings, the three-way stopcock allowed the Ideal BVM system to be connected to the
two-port media reservoir as well as maintain an extra port for cell sodding and media
injection.
Two-port media reservoirs were used in conjunction with the Ideal BVM system
and also functioned properly without any leakage. Liquid was pulled from the media
reservoir through the short outlet tube extending into the media and pumped through the
bioreactor system via a peristaltic pump. Liquid drops could be seen falling from the inlet
port, allowing for quick and easy visualization of flow as well as removal of air bubbles.
Media reservoirs were EO sterilized prior to use. A photo of the media reservoir setup is
shown below in Figure 3.31.
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Figure 3.31- Two-port media reservoirs in use. The two-port media reservoirs functioned
properly without leakage. Flow was established via a peristaltic pump.

Comparison of Ideal BVM System to Original BVM System
The Ideal BVM system and original BVM system were setup side-by-side by a
lab member and a user feedback survey was completed which compared the two systems.
Figures 3.32 and 3.33 below show the two systems being setup side-by-side and in the
incubator connected to a peristaltic pump. The criteria evaluated and the results of the
user feedback survey are summarized in Table 3.4. The completed user feedback survey
can be found in Appendix F.
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Figure 3.32- Side-by-side setup of original BVM and Ideal BVM systems. A lab member
performed a sterile setup of both systems.

Figure 3.33- Side-by-side setup of original BVM and Ideal BVM bioreactor systems.
Both systems were setup in the incubator and connected to a peristaltic pump to create
flow.

117

Original BVM System
Difficult

Easy

Ideal BVM System
Difficult

Easy

Overall Usability

1

2

3

4

5

1

2

3

4

5

Setup

1

2

3

4

5

1

2

3

4

5

Scaffold Assembly

1

2

3

4

5

1

2

3

4

5

Scaffold Insertion

1

2

3

4

5

1

2

3

4

5

Media Injection

1

2

3

4

5

1

2

3

4

5

Seal-Ability

1

2

3

4

5

1

2

3

4

5

Aseptic Use

1

2

3

4

5

1

2

3

4

5

Bioreactor Assembly

1

2

3

4

5

1

2

3

4

5

Control of Flow

1

2

3

4

5

1

2

3

4

5

Adjustability

1

2

3

4

5

1

2

3

4

5

Awkward
Components and Fittings

1

2

Convenient
3

Poor
Component Configuration

1

4

5

Excellent
2

3

4

5

Awkward
1

2

Convenient
3

Poor
1

4

5

Excellent
2

3

4

5

Table 3.4- Summary of user feedback survey. The Ideal BVM system and original BVM
system were compared based on the criteria listed.
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Based on the user feedback survey comments one of the advantages of the Ideal
BVM system was that the chamber lid can be sterilized separately from the rest of the
BVM chamber. In addition, the lid is not permanently attached to BVM chamber, and
does not need to be held open, freeing up a second hand for use during scaffold insertion
and work in the hood. Both these features were helpful in maintaining sterility and made
setup easier. Another noted advantage was that the four snapping latches of the lid
eliminated the need for tools when closing and sealing the BVM chamber. The Ideal
BVM system also utilized stopcocks instead of side clamps to control flow and since the
BVM chamber is not filled to the top with media the need to eliminate air bubbles during
setup was no longer a challenge. Finally, with inlet and outlet fittings arranged so that
only one configuration exists to setup the bioreactor system time was not wasted and
there was no confusion when connecting the Ideal BVM system to the two-port media
reservoir.
Based on the user feedback survey comments one of the disadvantages of the
Ideal BVM system was that a larger volume of media was needed to fill the BVM
chamber. Also, the larger container takes up more space in the incubator. However, it is
important to note that the increased chamber volume only requires a one-time fill, as
opposed to the reservoirs which are replaced every 3 days, and that these larger
containers are stackable. The disadvantages, therefore, are offset by the advantages of the
Ideal BVM system in comparison to the original BVM system.
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Blood Vessel Development
The Ideal BVM system successfully cultivated an in vitro blood vessel mimic by
supporting cell sodding and cultivation. The scaffold was aseptically inserted and human
umbilical artery smooth muscle cells (HUASMC) were pressure sodded onto the luminal
surface of the ePTFE scaffold. Cells adhered to the scaffold surface and were distributed
along the length of the vessel. Scanning electron microscope (SEM) images of an ePTFE
scaffold surface are shown below in Figures 3.34 and 3.35. An SEM image of bare
ePTFE, which represents the scaffold prior to cell sodding, is shown for reference
followed by SEM images of the ePTFE with cells adhered to the surface.

Figure 3.34- SEM image of bare ePTFE scaffold surface.
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Figure 3.35- SEM images of ePTFE scaffold surface with cells. The Ideal BVM system
successfully cultivated an in vitro blood vessel mimic with cell deposition and cell
adherence to the scaffold surface.

121

Discussion and Conclusions
The new Ideal BVM system and two-port media reservoirs were successfully built
and implemented. The work described in this chapter supports the use of the Ideal BVM
system for cultivation of in vitro blood vessel mimics. The finalized design and setup
procedures were described in detail with testing performed to validate and verify the
Ideal BVM bioreactor system functionality and use. The Ideal BVM incorporated a user
friendly design and assembly was simple and straightforward. The scaffold was easy to
insert without the need for bending or twisting. The leak-proof chamber was easy to seal
and permitted quick and sterile assembly in the hood. Scaffold length and diameter were
adjustable for greater testing variability. The chamber was optically clear allowing for
easy visibility of scaffold, media and stent placement and was sterilizable by ethylene
oxide (EO) gas. The Ideal BVM chamber was easy to manufacture without the need for
adhesive or special tooling and was constructed of materials and components that were
readily available and easy to obtain resulting in a low cost design that was easy to scale
up. Multiple chambers could be configured in the incubator and the use of biocompatible
materials allowed cells to grow and function.
These findings support the hypothesis that design changes could be made and new
configurations implemented to the original BVM system that would improve function
and usability for preclinical device testing. Specifically, the work described in this
chapter supports the hypothesis that a BVM chamber could be created which has the
advantages of easy graft insertion and seal-ability, as well as the ability to accommodate

122

varying sizes of vessel scaffolds, all while maintaining the needs of a tissue engineering
bioreactor system.
Several other bioreactor systems currently exist for development of tissue
engineered blood vessels (TEBV). Most of these systems, similar to the Ideal BVM
system, use a peristaltic pump to create flow within an optically clear chamber. However,
chamber design, scaffold orientation, and general configuration vary considerably. For
example, a custom designed vertical bioreactor chamber was built which housed a noncompliant silicone scaffold sodded with endothelial cells (EC) to examine the effects of
shear stress and intravascular pressure (Punchard, et al. 2007). A second design utilized a
large laboratory flask with sodding and cultivation of vascular smooth muscle cells
(VSMC) on a PLCL [poly-(lactide-co-caprolactone)] scaffold oriented vertically within
the chamber (Jeong, et al. 2005). These vertical bioreactor designs are shown below in
Figure 3.36. Two other designs which examined the effects of pulsatile flow on smooth
muscle and endothelial cell development utilized bioreactor systems that were very
similar to the Ideal BVM system, with horizontal scaffold orientation (Hoerstrup, et al.
2001; Engbers-Buijtenhuijs, et al. 2006). These systems were assembled so that many
scaffolds could be cultivated at once. Figure 3.37 shows the basic schematics of these two
horizontal systems. In comparison with these bioreactor systems, the Ideal BVM differed
in that it was designed for the purpose of preclinical testing. Therefore, separate
individual flow paths were needed for each system and the ability to scale-up was a large
focus. However, in general, each bioreactor system for the development of tissue
engineered blood vessels must be designed so that sterility is maintained at all times and
flow can be created through a scaffold lumen. Designs differ based on the available
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resources, desired features, purpose of the study, and designer ingenuity. In the case of
the Ideal BVM system specific criteria were set in advance which guided the overall
design.

Figure 3.36- Vertical bioreactor chambers.

(Permission granted to reprint image from Punchard, et al. 2007 published in Journal of
Biomechanics by Elsevier Limited.; Permission granted to reprint image from Jeong, et
al. 2005 published in Biomaterials by Elsevier Limited.; see Appendix G)
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Figure 3.37- Horizontal bioreactor systems.

(Permission granted to reprint image from Hoerstrup, et al. 2001 published in European
Journal of Cardio-Thoracic Surgery by Elsevier Limited.; Permission granted to reprint
image from Engbers-Buijtenhuijs, et al. 2006 published in Biomaterials by Elsevier
Limited.; see Appendix G)

An additional advantage of the Ideal BVM system is that the basic design used to
create the inlet and outlets of both the Ideal BVM chamber and two-port media reservoir
can be easily applied to a wide range of container shapes and sizes. Depending on need
and desired scaffold configuration holes can be placed in any location within the
container. For example, a larger container could allow for longer scaffold lengths, or
placement of inlet and outlet ports in varying configurations could accommodate more
physiologic scaffold orientations, such as bends and bifurcations. Also, if additional ports
are desired for injection of media into the space surrounding the scaffold, they can be
easily added at any location desired. It is important to note that as container length and
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size increase so does container volume. Volume of the BVM chamber is not a critical
factor, but does affect the amount of media needed to fill the system and should be
considered prior to implementing a different container size.
Given the possible variability of the general Ideal BVM chamber design, the
following chapter will explore the potential to create alternate chambers for the
evaluation of more complex vascular devices as well as the creation of chambers that
accommodate more physiological vascular models. This idea of next generation BVM
systems will be explored as potential future uses of the in vitro blood vessel mimic for
preclinical device testing.
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4. DESIGN OF NEXT GENERATION BVMs
Introduction
A BVM system can allow initial assessments to be performed on a large number
of coating combinations and stent configurations in order to direct animal and clinical
studies toward the most promising devices. The aim of the work in the previous chapters
was to improve upon the original BVM system by developing a new, more ideal design
and to describe in detail the finalized design, construction and setup of the Ideal BVM
system and the testing performed to validate and verify its functionality and use.
The design of both the original BVM and Ideal BVM systems focused on straight,
simple scaffold orientations representing simple lesions and single vessel disease
(Fournier, et al. 2005). Coronary stent implantation, however, is being performed in an
increasing number of patients with a wide spectrum of clinical and lesion characteristics.
The anatomical characteristics of coronary arteries vary considerably, ranging from
straight simple geometries to extremely angulated bends and curves as well as
bifurcations and long lesions (Ellis, et al. 1990; Zhu, et al. 2008; Smith, et al. 2001).
Depending on the individual, the anatomical structure of the coronary arteries can include
all or some of the characteristics identified above. These lesion characteristics, including
long lesions, angulated geometries, and bifurcations, will be described in detail below
and will provide an introduction to the aims of this chapter.
The Ideal BVM system was designed to test stents ranging from 2.0-5.0 mm
diameters and 8-38 mm lengths (Kandzari, Tcheng and Zidar 2002; Kraitzer, Kloog and
Zilberman 2008), in order to accommodate the variations of coronary arteries observed in
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clinical practice and the stents currently available in the market. However, single
coronary lesions are often longer than 38 mm, sometimes greater than 60 mm in length,
and treatment requires multiple overlapping stents (Ruchin, et al. 2008). Using the BVM
system for preclinical testing of overlapping stents could allow for better understanding
of the cellular response at the overlapping junctions as well as the effect of the potentially
double local drug does when using drug-eluting stents (Kang, et al. 2007). In addition,
new interlocking stent designs, such as the Custom NX(R) DES System manufactured by
XTENT, Inc., are exploring the possibility of deploying stents up to 60 mm in total length
(Stella, et al. 2008). Therefore, a BVM chamber for the preclinical testing of overlapping
and longer total stent lengths would be beneficial.
According to the American College of Cardiology/American Heart Association
(ACC/AHA) Guidelines for Percutaneous Coronary Intervention, non-angulated coronary
artery geometries are defined as bends that are less than 45°, while moderately angulated
geometries represents bends between 45° and 90°, and extremely angulated geometries
are considered bends in excess of 90° (Smith, et al. 2001). A variety of angled geometries
are illustrated below in Figure 4.1. Figure 4.2 is an X-ray angiogram image of the
coronary arteries and shows the variation of curvatures observed in clinical practice.
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a)

b)

d)

c)

e)

Figure 4.1- Coronary artery geometries. Non-angulated bends are between 0° (a) and 45°
(b), moderately angulated bends are between 45° and 90° (c), and extremely angulated
geometries are greater than 90°. Examples of extremely angulated geometries are shown
as 135° (d) and 180° (e).
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Figure 4.2- X-ray angiogram image of the coronary arteries. Various angled bends and
curvatures are present.

(Permission granted to reprint image from Xu, et al. 2007 published in Computer
Methods and Programs in Biomedicine by Elsevier Limited.; see Appendix G)

As mentioned previously, the Ideal BVM system was designed for straight,
simple scaffold orientations representing simple lesions and ideal anatomical geometry.
In clinical practice, however, coronary arteries are not straight and uniform. They run
along the surface of the heart and are curved, bent, and angulated (Smith, et al. 2001). In
addition, it has been observed that plaque accumulation is related to vessel curvature,
with plaque accumulating more rapidly in angulated vessels where wall shear stress is
low (Wahle, et al. 2006; Zhu, et al. 2008). As a result, stents are most often placed in
curved positions within the coronary arteries and remain in a bent position throughout
their lifetime (Fournier, et al. 2005; Smith, et al. 2001). Many coronary stents, such as the
MULTI-LINK manufactured by Abbott Vascular, CYPHER® manufactured by Cordis,
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and TAXUS® manufactured by Boston Scientific, also claim superior flexibility and
conformity which allow the stent to mold to the natural contours of the vessel wall
(Serruys and Gershlick 2005; Rieu, et al. 2003). Therefore, a BVM chamber for the
preclinical testing of devices in curved and angulated vessels would be beneficial and
would represent a more physiological blood vessel mimic model.
As described by the ACC/AHA a coronary bifurcation occurs when one main
vessel branches out into two smaller vessels, one being the continuation of the main
vessel, and the other referred to as the side branch (Smith, et al. 2001). A coronary
bifurcation lesion is defined as a narrowing involving both the main vessel and a
significant side branch (Louvard, et al. 2008). Illustrations of two bifurcated geometries,
Y-shaped and T-shaped, are shown below in Figure 4.3. Figure 4.4 is an X-ray angiogram
image of Y-shaped and T-shaped bifurcations observed in clinical practice.

a)

b)

Figure 4.3- Bifurcated coronary artery geometries. Y-shaped (a) and T-shaped (b).
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a)

b)

Figure 4.4- X-ray angiogram image of bifurcated coronary arteries.
Y-shaped (a) and T-shaped (b).

(Permission granted to reprint image from Ikeno, Buchbinder and Yeung 2007 published
in Cardiovascular Revascularization Medicine by Elsevier Limited.; see Appendix G)

Bifurcation lesions account for 15-18% of all coronary lesions and represent one
of the most complex coronary lesions to treat since the lumen of both the main vessel and
side branch are affected and require treatment (Sukhija, Mehta and Sachdeva 2008).
Recent advances have allowed physicians to treat bifurcation lesions, where both the
main vessel and side branch need to be restored. Many techniques, with the use of one or
multiple stents, have been developed to treat bifurcation lesions (Sukhija, Mehta and
Sachdeva 2008; Iakovou, Ge and Colombo 2005). The simplest approach is to stent the
main vessel and dilate the side branch through the stent struts. A second approach is to
use multiple stents and can be accomplished through a number of different techniques
which were discussed in Chapter 1: V-stenting, simultaneous kissing, crush, T-stenting,
modified T-stenting, Y-stenting, and skirt. Most recently, novel stents and delivery
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systems such as AXXESS™ manufactured by Devax, Inc., PETAL™ manufactured by
Boston Scientific, and MULTI-LINK Frontier manufactured by Abbott Vascular have
been developed specifically to treat bifurcation lesions (Grube, et al. 2007; Ikeno,
Buchbinder and Yeung 2007; Miyazawa, et al. 2007; Lefèvre, et al. 2005). Therefore, a
BVM chamber for the preclinical testing of devices in bifurcation shaped vessels would
be beneficial and would support advancing technology.
In summary, the variation and complexity of coronary artery disease and the
advanced capabilities to detect and determine the extent and severity of coronary lesions
has led to an increased interest in intravascular device innovation (Kini 2006). Stents are
most often placed in vessels with angulated geometries and remain in bent positions
throughout their lifetime (Fournier, et al. 2005; Smith, et al. 2001). Long lesions can
require two overlapping stents (Ruchin, et al. 2008) and bifurcation lesions often require
two stents at varying angles or the use of a novel stent specifically designed for a
bifurcation (Sukhija, Mehta and Sachdeva 2008; Ikeno, Buchbinder and Yeung 2007).
Thus, the aim of the work in this chapter was to expand the BVM concept to meet the
need of future technologies that currently have not been adequately addressed in
preclinical models, such as long, angulated and bifurcation lesions. The hypothesis was
that the need to test stents specifically for long, angulated and bifurcation lesions can be
potentially addressed by using modified BVM systems. Although full implementation
and testing of these models is beyond the scope of this thesis, the current work will
explore the development of new and innovative models for the evaluation of more
complex lesions as well as the creation of chambers that accommodate more
physiological vascular models and scaffold orientations. Therefore, this chapter will
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explore the creation of alternate chambers for the evaluation of more complex vascular
devices as potential future uses of the in vitro blood vessel mimic for preclinical device
testing.
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Next Generation BVM System Designs
BVM System for Long Vessels
A BVM system for long vessels can be created by using a longer chamber, such
as the 800 ml, 8" x 5" x 2", semitransparent, polypropylene rectangular snap and seal
leak-proof food container (Lock & Lock P/N HPL816) and implementing the same
design and construction described in the previous chapter and detailed in Appendix C for
the assembly of the luminal inlet and luminal outlets. Locations of the luminal inlet and
luminal outlets are identical to the Ideal BVM system. A chamber of this size can
accommodate scaffold lengths up to 170 mm which would allow long or multiple stents
to be placed and overlapped within the vessel lumen. It is important to note that the
volume of this chamber is greater than that of the Ideal BVM system. Volume of the
BVM chamber is not a critical factor, but does affect the amount of media needed to
initially fill the system and should be considered prior to implementation. The BVM
system for long vessels is modeled below in Figures 4.5 and 4.6.

Figure 4.5- BVM system for long vessels.
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Figure 4.6- Scaffold setup for long vessels. Longer scaffold lengths can be
accommodated in a modified BVM system by using a longer chamber.

Scaffold setup and insertion for the BVM system for long vessels will remain
unchanged from the assembly process used for the Ideal BVM system described in the
previous chapter, except for the length of ePTFE scaffold used. As in the previous design,
male luer integral lock ring to female luer thread style couplers can be used to vary the
overall scaffold length. A prototype of this model would be needed to establish the
corresponding scaffold length versus number of couplers used.
The design of the BVM system for long vessels is almost identical to the Ideal
BVM system and implements a chamber that is identical except for length and volume.
As a result the BVM chamber for long vessels meets all of the design criteria established
in the previous chapters.
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BVM System for Angulated Vessels
A BVM system for angulated and curved vessels can be created by varying the
placement of the luminal inlet and luminal outlet holes on the Ideal BVM chamber.
Construction of the luminal inlet and luminal outlet holes can be accomplished using the
same materials and methods described in the previous chapter and detailed in Appendix
C. Prototypes must be built in order to determine the exact dimensional location and
placement of the luminal inlet and luminal outlet holes. However, the illustrations below
approximate their general locations. A large variation of curves and angles can be created
ranging from slight bends to 180° turns, representing non-angulated, moderately
angulated and severely angulated geometries. Construction of several modified BVM
chambers for angulated vessels are described below. All designs utilize the same chamber
as the Ideal BVM system, a 350 ml, 4" x 5" x 2", semitransparent, polypropylene
rectangular snap and seal leak-proof food container (Lock & Lock P/N HPL806).
The simplest bend that can be created requires only one change to the tubing
configuration of the Ideal BVM system. Locations of the luminal inlet and luminal outlet
holes are identical to the Ideal BVM system. By reversing the placement of the luminal
outlet and extra luminal outlet and connecting the scaffold as described in the previous
chapter, a slightly bent scaffold can be accommodated. This setup represents a nonangulated geometry and can accommodate scaffold orientations with bends of 45° or less.
The BVM system for slightly bent vessels is modeled below in Figures 4.7 and 4.8.
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Figure 4.7- BVM system for slightly bent vessels.

Figure 4.8- Scaffold setup for non-angulated vessels. A slightly bent scaffold can be
accommodated in a modified BVM chamber by reversing the luminal outlet and extra
luminal outlet positions.

The second bend that can be created requires only a slight modification to the
configuration of the Ideal BVM system. By moving the luminal outlet and extra luminal
outlet to the long side of the chamber and connecting the scaffold as described in the
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previous chapter, a moderately angled scaffold can be accommodated. This setup
represents moderately angled geometry and can accommodate a scaffold orientation with
a bend of 90°. The BVM system for moderately angled vessels is modeled below in
Figures 4.9 and 4.10.

Figure 4.9- BVM system for moderately angled vessels.

Figure 4.10- Scaffold setup for moderately angulated vessels. A moderately angled
scaffold of 90° can be accommodated in a modified BVM chamber by moving the
luminal outlet and extra luminal outlet to the long side of the chamber.
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The third bend that can be created requires a minor modification to the
configuration of the Ideal BVM system. By moving the luminal inlet, luminal outlet and
extra luminal outlet to the long side of the chamber and connecting the scaffold as
described in the previous chapter, a severely angled scaffold can be accommodated. This
setup represents severely angled geometry and can accommodate a scaffold orientation
with a bend of 180°. The BVM system for severely angled vessels is modeled below in
Figures 4.11 and 4.12.

Figure 4.11- BVM system for severely angled vessels.
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Figure 4.12- Scaffold setup for severely angulated vessels. A severely angled scaffold of
180° can be accommodated in a modified BVM chamber by moving the luminal inlet,
luminal outlet and extra luminal outlet to the long side of the chamber.

Scaffold setup and insertion for the BVM systems for angulated vessels will
remain unchanged from the assembly process used for the Ideal BVM system described
in the previous chapter, except for the lengths of ePTFE scaffolds used. As in the
previous design, male luer integral lock ring to female luer thread style couplers can be
used to vary the overall scaffold lengths in each design. Prototypes of each model are
needed to establish the corresponding scaffold lengths versus number of couplers.
One challenge that may be encountered in these configurations is kinking and
occlusion of the scaffolds due to their bent orientations. However, ePTFE material is
flexible and compliant and once flow is created via a peristaltic pump, the force on the
scaffold walls created by the pressure of the media may be strong enough to overcome
any kinks or occluded bends that occur. This hypothesis will need to be verified and
tested with full-scale prototypes. If kinking or occlusion proves to be a challenge a
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change in the scaffold material or fabrication method may need to be addressed. Preforming the scaffold in a bent orientation by using a mold or customized model could
provide a solution. A thin wire coiled around the outside of the ePTFE could also be used
to control the curvature and orientation without disrupting the inner lumen.
The designs of the BVM systems for angulated vessels are almost identical to the
Ideal BVM system and use the exact same chamber. As a result the BVM chambers for
angulated vessels meet all of the design criteria established in the previous chapters.

BVM System for Bifurcation Vessels
A BVM system for bifurcation vessels can be created by varying the placement of
the luminal inlet, luminal outlet, and extra luminal outlet holes and adding a second
luminal outlet to accommodate the side branch lumen. Construction of the luminal inlet
and luminal outlet holes can be accomplished using the same materials and methods
described in the previous chapter and detailed in Appendix C. Prototypes must be built in
order to determine the exact dimensional location and placement of the luminal inlet and
luminal outlet holes. However, the illustrations below approximate their general
locations. The most notable change is the modified tubing configuration which is
necessary to accommodate flow through the second luminal outlet. Construction of two
modified BVM chambers for Y-shaped and T-shaped bifurcation vessels are described
below. Each design utilizes the same chamber as the Ideal BVM system, a 350 ml, 4" x
5" x 2", semitransparent, polypropylene rectangular snap and seal leak-proof food
container (Lock & Lock P/N HPL806).
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The first bifurcation geometry that can be created requires some modifications to
the configuration of the Ideal BVM system. By moving the extra luminal outlet to the
long side of the chamber and adding a second luminal outlet in its place a Y-shaped
bifurcation scaffold can be accommodated. A Y-shaped bifurcation scaffold can be setup
and connected as described in the previous chapter with the addition of one female luer
thread style to 200 series barb, 1/8" ID tubing (Value Plastics P/N FTLL230-1). One
male-to-male luer lock connector, with one rotating collar (Qosina P/N 17644) also needs
to be attached to the second outlet to hold the scaffold. The easiest way to configure the
tubing is to simply add a second Y-connector with 200 series barbs, 1/8" ID tubing
(Value Plastics P/N Y230-1) prior to the attachment of the one-way stopcock. In addition,
a second one-way stopcock (Value Plastics P/N VP455980) must be added to the second
luminal outlet to control flow. This modified orientation represents Y-shaped bifurcation
geometry and can accommodate a Y-shaped scaffold. The BVM system for Y-shaped
bifurcation vessels is modeled below in Figures 4.13 and 4.14.

Figure 4.13- BVM system for Y-shaped bifurcation vessels.
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Figure 4.14- Scaffold setup for Y-shaped bifurcation vessels. A Y-shaped bifurcation
scaffold can be accommodated in a modified BVM chamber by moving the extra luminal
outlet to the long side of the chamber and adding a second luminal outlet in its place.

The second bifurcation geometry that can be created requires one simple
modification to the configuration of the Ideal BVM system. By adding a second luminal
outlet to the long side of the chamber a T-shaped bifurcation scaffold can be
accommodated. A T-shaped bifurcation scaffold can be setup and connected as described
in the previous chapter with the addition of one female luer thread style to 200 series
barb, 1/8" ID tubing (Value Plastics P/N FTLL230-1). One male-to-male luer lock
connector, with one rotating collar (Qosina P/N 17644) also needs to be attached to the
second outlet to hold the scaffold. The easiest way to configure the tubing is to simply
add a second Y-connector with 200 series barbs, 1/8" ID tubing (Value Plastics P/N
Y230-1) prior to the attachment of the one-way stopcock. In addition, a second one-way
stopcock (Value Plastics P/N VP455980) must be added to the second luminal outlet to
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control flow. This modified orientation represents T-shaped bifurcation geometry and can
accommodate a T-shaped scaffold. The BVM system for T-shaped bifurcation vessels is
modeled below in Figures 4.15 and 4.16.

Figure 4.15- BVM system for T-shaped bifurcation vessels.

Figure 4.16- Scaffold setup for T-shaped bifurcation vessels. A T-shaped bifurcation
scaffold can be accommodated in a modified BVM chamber by adding a second luminal
outlet to the long side of the chamber.

145

Scaffold setup and insertion for the BVM systems for bifurcation vessels will
remain unchanged from the assembly process used for the Ideal BVM system described
in the previous chapter. However, Y-shaped and T-shaped bifurcation ePTFE scaffolds
will need to be constructed. Sewing standard ePTFE material together in the desired
shape could provide a feasible method and is illustrated in Figures 4.17 and 4.18 below.

Figure 4.17- Y-shaped bifurcation scaffold. Constructed by sewing three short pieces of
ePTFE material together.
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Figure 4.18- T-shaped bifurcation scaffold. Constructed by creating a hole in the center
of a long piece of ePTFE material and sewing a short piece of ePTFE material to the hole.

One challenge that may be encountered with this assembly process is leakage at
the suture sites. Prototype scaffolds will need to be constructed and inserted into the
BVM chambers and flow via a peristaltic pump will need to be initiated to evaluate the
potential leakage. Using a mold or customized model to form the entire scaffold in a
bifurcation shape could also provide a solution and would eliminate the possibility of
leakage, although a material other than ePTFE would need to be chosen and evaluated.
As in the previous design, male luer integral lock ring to female luer thread style couplers
can be used to vary the overall scaffold lengths in each design. Prototypes of each model
are needed to establish the corresponding scaffold lengths versus number of couplers.
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The designs of the BVM systems for bifurcation vessels are very similar to the
Ideal BVM system and use the exact same chamber. As a result the BVM chambers for
bifurcation vessels meet all of the design criteria established in the previous chapters.
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Next Generation BVM System Prototypes
Six modified BVM systems representing complex coronary vessel geometries
were modeled above: long, slightly bent, moderately angulated, severely angulated, Yshaped bifurcation and T-shaped bifurcation. Although full implementation and testing of
these models is beyond the scope of this thesis, a multipurpose and Y-shaped bifurcation
BVM system prototype were built with the intention of verifying the feasibility of these
designs. The only configuration that was not prototyped was the BVM system for long
vessels, since the configuration is identical to the Ideal BVM system with the exception
of a longer chamber.

Multipurpose BVM System
Instead of building each individual BVM system prototype, a multipurpose BVM
system was built with appropriate luminal inlets and luminal outlets to accommodate
complex vessel configurations. This modified BVM chamber accommodated slightly
bent, moderately angulated, severely angulated, and T-shaped bifurcation configurations.
The luminal inlets and luminal outlets that were not required for a specific configuration
were simply occluded using a male luer integral lock ring plug (Value Plastics P/N LP41). As proposed, two pieces of ePTFE material were sutured together to make the Tshaped bifurcation scaffold. The multipurpose BVM system prototype, with a slightly
bent scaffold, a moderately angulated 90° scaffold, a severely angulated 180° scaffold,
and a T-shaped bifurcation scaffold are shown below in Figures 4.19 through 4.22.

149

Figure 4.19- Multipurpose BVM System with a slightly bent scaffold.
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Figure 4.20- Multipurpose BVM System with a moderately angulated 90° scaffold.
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Figure 4.21- Multipurpose BVM System with a severely angulated 180° scaffold.
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Figure 4.22- Multipurpose BVM System with a T-shaped bifurcation scaffold.
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Y-Shaped Bifurcation BVM System
A Y-shaped bifurcation BVM system was built with appropriate luminal inlets
and luminal outlets to accommodate a Y-shaped bifurcation vessel configuration.
However, instead of suturing three separate piece of ePTFE together, as purposed, a
simpler method was used. Due to the flexibility of ePTFE material and the desire to use
as few sutures as possible, the arms of the T-shaped scaffold were bent upwards to create
a Y-shaped scaffold. This method eliminated the need for three separate ePTFE pieces to
be sutured together, reducing the chance of leakage at the suture points. The Y-Shaped
Bifurcation BVM system prototype is shown below in Figure 4.23.
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Figure 4.23- Y-Shaped Bifurcation BVM System with a Y-shaped bifurcation scaffold.
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Discussion and Conclusions
The next generation BVM systems, presented through computer-generated
models and initial prototypes, represent the development of new and innovative designs
for the evaluation of more complex lesions that currently have not been adequately
addressed in preclinical models and support the hypothesis that the Ideal BVM system
can be modified to accommodate advancing technology. The work in this chapter
expanded the BVM concept to meet the needs of long, angulated and bifurcation lesions.
Alternate chambers for the evaluation of more complex vascular devices, as potential
future uses of the in vitro blood vessel mimic for preclinical device testing, were
illustrated and prototyped.
Full implementation and testing of the modified BVM systems was beyond the
scope of this thesis. Additional prototypes and verification testing is needed to
demonstrate that the modified BVM systems developed in this chapter meet the testing
needs for long, angulated and bifurcation lesions. The prototypes of each modified BVM
chamber need to be finalized and the entire bioreactor system needs to be assembled and
connected to a peristaltic pump. Scaffolds for each system also need to be assembled,
measured and connected to the modified BVM systems to establish lengths, and evaluate
the possibility for kinking or occlusion due to bent orientations. Bifurcation scaffolds will
need to be constructed and evaluated for their ability to function under pressure and flow
conditions.
The first step in the evaluation of each model requires full construction of the
modified BVM systems. Construction of the modified BVM chambers utilize the same
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materials and methods described in the previous chapter and detailed in Appendix C.
Location of the luminal inlets and outlets vary between models, but the assembly process
remains unchanged. The construction of a multipurpose and Y-shaped bifurcation BVM
chamber prototype and the assembly of each complex vessel scaffold configuration
within these chambers were shown, verifying the feasibility of these designs.
The complete bioreactor configurations, although not illustrated in this chapter,
consist of the modified BVM systems and two-port media reservoirs, described in the
previous chapter, connected in series. Setup is identical to the Ideal BVM bioreactor
configuration and only two simple connections need to be made. Specific placement of
male luer lock and female luer thread fittings ensure proper setup and orientation every
time. Only one configuration exists for setting up the modified BVM bioreactor systems,
since the fittings of all modified BVM chambers and two-port media reservoirs were
designed as male-to-female connections.
The luminal inlet, luminal outlets and extra luminal outlet tubing configurations
are identical to the Ideal BVM system and permit variation in flow path. Transluminal
and transmural flow are easily controlled via the one-way stopcocks attached to the
luminal outlets. For the bifurcation models, one-way stopcocks are attached to both the
main vessel luminal outlet and the side branch luminal outlet, allowing control of flow
through each of the bifurcation paths. By closing off the luminal outlet paths, through the
use of the one-way stopcocks, transmural flow through the porous ePTFE scaffold walls
is created, with flow exiting the extra luminal outlets. Transmural flow is used for
conditioning and cell sodding of the scaffold material. By opening the one-way
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stopcocks, transluminal flow is restored through the luminal outlets. The one-way
stopcocks are easy to use and provide a quick and simple method for controlling the flow
paths. The levers are easy to turn and once in position flow is immediately and firmly
blocked. The merging of the luminal outlets and extra luminal outlets into one main
outlet via Y-connectors make attachment to the two-port media reservoir simple with the
need for only one connection. The three-way stopcocks attached to the luminal inlets
easily function as both flow paths and cell sodding ports. With two female luer thread
fittings, the three-way stopcocks allow the modified BVM systems to be connected to the
two-port media reservoirs as well as maintain an extra port for cell sodding and media
injection.
Few models, other than animal and clinical studies, exist for preclinical testing of
complex intravascular devices designed specifically for placement in complex coronary
lesion geometries. Currently most preclinical biocompatibility and tissue response testing
is done on animals in outside laboratories which is both time consuming and expensive,
especially when testing involves device placement and orientation in long, angulated and
bifurcation vessels. Although preclinical animal studies are accepted as a means to
predict the probability of device safety and effectiveness in humans, the need exists for
preclinical testing using live human tissue. Preclinical testing using human cells would
greatly increase the medical community’s understanding of tissue response to complex
intravascular devices prior to animal and patient testing and prior to device release into
the market. Presently, it is difficult to simulate device and tissue interaction and research
still needs to be done to fully understand tissue behavior and the in vivo interaction that
occurs between device and tissue in complex coronary lesion geometries.
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In order to address some of these limitations, there has been research on the use of
alternate or in vitro models for this type of complex device testing. One research group
that wanted to evaluate the use of coronary stents in the side branch of a bifurcation
lesion constructed a testing model made of Plexiglas with a 4.5 mm bifurcation shaped
trough bored out of the center in order to simulate a bifurcation vessel (Ormiston, et al.
1999). This type of synthetic model approach is not uncommon, and the model does
allow stents to be deployed and evaluated in a bifurcated geometry, however no cellular
lining exists to provide physiological response evaluations. A second research group that
wanted to evaluate the response of endothelial cells to flow hemodynamics at an arterial
bifurcation apex constructed a T-shaped bifurcation in vitro flow chamber (Szymanski, et
al. 2008). This chamber was custom designed and constructed of polycarbonate, stainless
steel, and nylon, which are all autoclavable materials. This model, unlike the previous
model, was constructed for the purpose of establishing a cellular lining at the bifurcation
apex. However, intravascular devices were not deployed in this model and it is not clear
if the design allows for this type of evaluation.
With increasing complexity of coated stents and devices that interface with cells
and tissue (Waksman 2007; Waksman 2002; Sharkawi, et al. 2007) the ability to evaluate
in a living environment is crucial. The modified BVM systems developed in this chapter
were designed to support the growth of 3-dimensional in vitro tissue engineered blood
vessel mimics in order to provide physiological models of complex coronary geometries.
With advancing technology these modified BVM systems may one day provide an ideal
environment for evaluation of complex vascular devices and direct animal and clinical
studies toward the most promising advances.
159

5. DISCUSSION AND CONCLUSIONS
To summarize, the work in this thesis describes the design and optimization of an
in vitro blood vessel mimic (BVM) bioreactor system for the evaluation of intravascular
devices, specifically coronary stents, in simple and complex vessel geometries. The
general hypothesis driving this thesis project was that design changes could be made and
new configurations implemented to the existing blood vessel mimic system (Cardinal, et
al. 2006) that would improve function and usability for preclinical device testing. In order
to test this hypothesis, research was conducted based on two specific aims. The first aim
was to develop a more ideal BVM system. The specific hypothesis in this case was that a
BVM chamber could be created to accommodate a wider range of stent lengths and
diameters, while allowing for easy graft insertion and seal-ability. The second aim was to
develop next generation BVM systems, focused on future needs and technology. The
hypothesis in this case was that with emerging technology the ability to test stents
specifically for bifurcation lesions, as well as in long and angulated vessels, will be
needed and is possible within the BVM system. The prototypes developed and the
findings from constructed models were presented and discussed in the previous chapters
and support the hypotheses stated above.
The more ideal BVM bioreactor system designed and developed in this thesis was
successfully built and implemented. A more user friendly design was one of the primary
needs met by the Ideal BVM system. Easy scaffold insertion, without the need for
bending or twisting, along with a method to quickly and simply seal the vessel chamber
without the need for tools, greatly improved the usability of the BVM system. As
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discussed in detail in the introduction to this thesis, stents range in shape and size, and the
Ideal BVM system was designed to accommodate stent sizes ranging from 2.0-5.0 mm
diameters and 8-38 mm lengths in order to fit the variations of coronary arteries observed
in clinical practice and the stents currently available in the market. In addition, the Ideal
BVM chamber was easy to manufacture without the need for adhesive or special tooling
and was constructed of materials and components that were readily available and easy to
obtain resulting in a low cost design that was easy to scale up. Multiple chambers could
be configured in the incubator and the use of biocompatible materials allowed cells to
grow and function. Therefore, the work described in this thesis supports the use of the
Ideal BVM system for cultivation of in vitro blood vessel mimics.
The next generation BVM systems, presented in this thesis through computergenerated models and initial prototypes, represent the development of new and innovative
designs for the evaluation of more complex lesions that currently have not been
adequately addressed in preclinical models. The work presented supports the hypothesis
that the Ideal BVM system can be modified to accommodate advancing technology.
Alternate chambers for the evaluation of more complex vascular devices, as potential
future uses of the blood vessel mimic system for preclinical device testing, were
illustrated and prototyped. Full implementation and testing of the modified BVM systems
was beyond the scope of this thesis. However, the construction of a multipurpose and Yshaped bifurcation BVM chamber prototype and the assembly of each complex vessel
scaffold configuration within these chambers were shown, verifying the feasibility of
these designs. With advancing technology, these modified BVM systems may one day
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provide an ideal environment for evaluation of complex vascular devices in order to
direct animal and clinical studies toward the most promising technologies.
The goal of this thesis was to not only expand upon the original BVM model, but
to develop new and innovative models for the evaluation of devices in more complex
geometries such as bifurcations, long and angulated vessels. The BVM systems
developed in this thesis are model systems which were developed for the initial testing of
newly emerging intravascular technology, and represent the next step in preclinical
device testing. In the following sections, key aspects of this field and relevant areas of
research will be discussed with regard to the present thesis work.
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Preclinical Intravascular Device Testing
Preclinical device testing is a crucial step in the process of developing and
releasing new medical devices to the market. The objective of preclinical testing is to
provide preliminary evidence of product safety and efficacy in order to support the
initiation of human clinical trials. Preclinical testing typically begins using models and
methods that are simple and cost-effective in order to identify potential failures as early
in the development process as possible, and then progresses to models with increasing
complexity. As discussed in the introduction, preclinical intravascular device testing is
currently performed using both in vitro laboratory models and in vivo animal models and
provides critical information about cellular and tissue responses as well as device
success.
Although preclinical animal studies are accepted as a means to predict the
probability of device safety and effectiveness in humans, no animal model can provide
complete insights into the human healing response following stent implantation.
Preclinical testing using human cells would greatly increase the medical community’s
understanding of tissue response to a specific device prior to animal and patient testing
and prior to device release. The Ideal BVM system developed in this thesis represents an
intermediate testing environment for assessing human cellular responses to intravascular
stents in a manner that combines the advantages of both in vitro and in vivo approaches.
The Ideal BVM system mimics the geometries of the coronary arteries and utilizes
human cells, which provide the potential for more predictive preclinical results than
animal models alone can provide. The Ideal BVM system developed in this thesis
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provides a feasible method to rapidly evaluate human tissue response to varying stent
configurations, materials, drugs and coatings as they become available. Although the
Ideal BVM system is not a substitute or replacement for animal models, it has the
potential to provide researchers with a more relevant in vitro tissue model that can be
used for the preclinical evaluation of new intravascular devices. The major advantage of
the in vitro blood vessel mimic system developed in this thesis is its potential for
consistent high-throughput evaluation of cellular response to advancing intravascular
technologies (Cheng, Lai and Kisaalita 2008; Yliperttula, et al. 2008).

Laminar Flow and Wall Shear Stress
One area that has not yet been addressed as a potential use for the blood vessel
mimic (BVM) bioreactor systems developed in this thesis is the study of laminar flow
and wall shear stress in stented vessels. Implanted stents can alter coronary flow and
induce significant changes in flow hemodynamics, especially in bifurcated and angulated
geometries where flow is already disturbed and shear stress is low (Zhu, et al. 2008;
Wahle, et al. 2006; Benard, et al. 2003). These changes result in local modification of the
mechanical stress exerted on the endothelial cells lining the vessel wall and several
studies have demonstrated that endothelial cell proliferation increases significantly when
subjected to weak shear stress and non-laminar flow (Ridger, et al. 2008; Scott 2006).
A number of experiments have been performed to study the influence of an
implanted stent on flow hemodynamics through a stented vessel (Peacock, et al. 1995;
Benard, et al. 2003). However, most of these studies used computer generated
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computational techniques rather than animal or in vitro physical models (Balossino, et al.
2008; Dehlaghi, Shadpoor and Najarian 2008). As a result, the influence of flow
disturbances on the healing response to an implanted stent is poorly understood and the
need exists for anatomically realistic testing models with cellular linings to obtain more
predictive preclinical results.
The use of the BVM systems developed in this thesis to study flow
hemodynamics in stented vessels could provide important information about the
influence of flow and shear stress on vascular healing. The BVM system could be used to
not only study the cellular response to laminar flow and shear stress changes due to the
presence of a stent, but could provide a model that would simultaneously allow for direct
flow and velocity measurements. The BVM bioreactor system created in this thesis is a
closed system in which all physical parameters, including flow, can be tightly controlled
and monitored while allowing visualization and access to the inner lumen of the stented
vessel. These advantages make the in vitro BVM system an ideal model for the study of
flow hemodynamics.

Drug Elution Kinetics
Blood flow through a stented vessel not only affects laminar flow and wall shear
stress, but plays a direct role on drug elution kinetics, or drug release, from drug eluting
stents (Umashankar, Hari and Sreenivasan 2007). As discussed in the introduction to this
thesis, a drug eluting stent is a device that releases a single or multiple bioactive agents
into the bloodstream that affect the tissue adjacent to the stent. Currently there are three
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different approaches to binding drugs to coronary stents: drug binding by means of a
polymer on the stent surface, drug binding aided by an inorganic stent coating, or direct
drug binding to the stent surface without coating (Acharya and Park 2006). Most often
drugs are either chemically bonded to the surface of the stent or trapped within a polymer
film or porous ceramic that allows controlled drug release (Kandzari, Tcheng and Zidar
2002). Drug release in biodegradable coatings is achieved through disintegration of the
biodegradable polymer of the stent, while non-biodegradable coatings release drugs by
allowing the drugs to diffuse through a porous matrix. Whatever mechanism of drug
binding used flow characteristics can have a significant influence on drug release and
distribution within the tissue of the stented vessel (Neubert, et al. 2008).
Currently, most preclinical drug elution studies consist of immersion of the drug
eluting stent in a small volume of liquid, with drug concentration measurements taken
over time or the use of computer generated computational models (Neubert, et al. 2008;
Balakrishnan, et al. 2007; Alexis, et al. 2004). These methods allow for the examination
of drug release but lack simulation of the vessel wall and cellular response and their
possible influence on drug release and distribution. The examination of in vivo release
and distribution is also limited since the drug concentrations in animals and humans
cannot reliably be estimated due to low systemic blood concentrations and the fact that
blood levels do not necessarily correspond to drug concentration at the stented lesion
(Neubert, et al. 2008). Due to these limitations an in vitro model would be extremely
valuable for the preclinical evaluation of drug elution kinetics.
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The use of the in vitro BVM system developed in this thesis could provide a
beneficial model for the study of drug elution kinetics. The BVM system provides an
environment that could allow for observation and measurement of drug release and
distribution within the vessel. With the addition of a cellular layer, the cellular response
to drug concentrations in the blood and tissue could be better understood and a closed
bioreactor system would permit precise drug concentration measurements at specific
points in time. Drug concentrations in the BVM system could be easily measured in the
circulating media, as well as in the media surrounding the scaffold, and in the scaffold
and cellular layer itself. These types of measurements could provide important
information on the influence of living tissue to drug release, distribution and local tissue
affects which in turn could provide insight into the role of drug eluting stents on the
cellular healing response and restenosis.

Delivery Systems
Much of this thesis has focused on the use of the BVM system to evaluate tissue
response to implanted stents. However, as discussed in the introduction, in addition to the
advancements in coronary stent design, the method of delivering these therapies has also
improved. These improvements have made percutaneous coronary intervention
procedures easier to perform and have reduced the amount of time for a single procedure.
Percutaneous coronary intervention in complex coronary geometries is difficult
and the increased complexity results in reduced success rates (Saeed, Banerjee and
Brilakis 2008). Therefore, novel delivery systems, smaller catheters, lower profile
167

balloons and other devices have been created to overcome the challenges associated with
tortuous anatomies. Stent delivery is an area of active research and a living model system
for testing and evaluating these new delivery devices would be ideal for development and
progression of the field.
The future of the BVM system developed in this thesis has the potential to be
used not only to evaluated tissue response to stent implantation but to the stent delivery
processes and systems themselves. The BVM system could allow researchers to quickly
evaluate the ability of the delivery system to safely and effectively implant a stent into a
coronary vessel, with the advantage of observing tissue response to the delivery device,
as well as the implanted stent.
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The BVM Concept for Other Tissues
Given the possible variability of the general BVM system concept, the following
section will explore the potential to create chambers for the evaluation of medical devices
in varying physiological tissue models. The BVM system developed in this thesis was
designed to mimic coronary blood vessels and vascular tissue. However, the general
concept can be used to model any tube like structure in which flow is present and has the
potential to provide in vitro models of a wide variety of human tissues.

Urology
The ureter is a narrow muscular tube in which urine flows from the kidney to the
bladder. A ureter may become obstructed as a result of a number of conditions including
strictures, inflammation, cancer and kidney stones. When the ureter is obstructed, urine is
unable to drain from the kidney and leads to pain, infection and if left untreated, kidney
failure. Therefore, action must be taken to restore the flow of urine to the bladder.
Ureteral stenting represents a minimally invasive procedure in which a ureteral
stent, a small diameter plastic tube with pigtail shaped ends, is temporarily placed
between the kidney and bladder to restore the flow of urine and provide a physical
scaffold for the healing ureter. Ureteral stents have widespread use in current urological
practice and are used for a wide variety of indications, the most common being the relief
of urinary stone disease. Ureteral stents are used to maintain ureteral patency after
endourological procedures and relive ureteral obstruction.
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One significant complication associated with ureteral stent placement is
encrustation within the stent lumen, blocking the flow of urine (Laube, et al. 2008;
Tunney, Keane and Gorman 1997). Infection and pain are also common complications.
As a result a number of new ureteral stent designs, materials, and coatings have been
introduced to the market with the goal of preventing bacterial buildup and encrustation
while increasing patient comfort (Kleinen, Böde and Laube 2008; Wignall, et al. 2008;
Cadieux, et al. 2006; Hafron, et al. 2006).
Several in vitro models have been developed for the preclinical testing of ureteral
stents (Gorman, et al. 2003; Choong, Wood and Whitfield 2000; Stoller, et al. 2000).
These models allow ureteral stents to be deployed and evaluated in anatomical
geometries; however, no cellular lining exists to provide physiological response
evaluations. Through the creation of an in vitro tissue engineered ureter construct a model
system could be established for the initial testing of newly emerging urological
technology. The need exists for new and advanced preclinical urological testing models
that provide medical device manufacturers and researchers with the ability to quickly
evaluate tissue response to new ureteral stent designs, materials and coatings.

Abdominal Aortic Aneurysm
Abdominal aortic aneurysm (AAA) is a common vascular disorder affecting
approximately 5% of the male population over 55 years of age (Chong and How 2004).
An abdominal aortic aneurysm occurs when a weak area of the abdominal aorta expands
or bulges due to the high pressure of blood flowing through it. AAA is a significant
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health risk since the aneurysm can burst or rupture at any time leading to severe bleeding,
shock and death (Iribarren, et al. 2007). Therefore, action must be taken to ensure that if
rupture or leakage occurs, blood flow through the abdominal aorta is not disrupted.
Until recently, open surgical replacement of the diseased aortic segment with a
prosthetic graft was the standard treatment for AAA (Steingruber, et al. 2006; Chong and
How 2004). Endovascular aortic aneurysm repair (EVAR), however, has become an
increasingly successful minimally invasive procedure for treating AAA. During EVAR
an endovascular stent-graft is permanently placed within the abdominal aorta at the site
of the aneurysm. The stent-graft provides a path for blood to flow through the aneurysm,
reducing the pressure exerted on the weakened walls.
There are significant complications associated with EVAR due to the high
velocity flow and pressures present in the abdominal aorta. Complications include
downstream migration of the stent-graft and leakage at the attachment site (Steingruber,
et al. 2006). As a result development of the ideal endovascular stent-graft is ongoing and
the need exists for an in vitro AAA flow model for evaluating endovascular fixation
techniques, new stent-graft designs and materials, long term durability and the cellular
response to these new technologies (Sulaiman, et al. 2008). Through the creation of an in
vitro tissue engineered large diameter vessel construct a model system could be
established for the initial testing of newly emerging AAA technology.

171

Potential as a Commercial Device
The BVM systems developed in this thesis have the potential to be created on a
large scale and sold to the biomedical industry as commercial preclinical testing devices.
The BVM system could be marketed as an in vitro bench-top testing apparatus that
mimics the human coronary artery environment. The BVM system could allow medical
device manufacturers and researchers to conduct their own individual preclinical
biocompatibility testing on a number of designs using a predictive model which could
reduce the number of animal studies required. The Multipurpose BVM, especially, has
the potential to be an ideal preclinical model since simple and complex vessel scaffolds
can be accommodated allowing researchers to test devices in a number of vessel
geometries. This type of preclinical testing may lead to better understanding of device
and tissue interaction much earlier in the development process and give researchers the
chance to make design improvements prior to animal and clinical studies.
In order to market the BVM system as a commercial device, additional work
would need to be completed. Extensive studies and comparisons would need to be made
between the results obtained from the BVM system and animal models. Research would
be needed to demonstrate that the BVM system provides predictive preclinical results that
are comparable to those obtained from animal and clinical studies. Besides additional
laboratory testing, ship testing would need to be performed to ensure that the BVM
system can be transported without sustaining physical damage. In addition, testing would
need to be conducted to ensure that the cells provided with the system are stored and
packaged properly so that they survive shipment. Other considerations that would need to
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be addressed include determining the number of times the system can be sterilized and
reused prior to failure, the creation of detailed instructions for use, and large scale
manufacturing ability.
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Limitations and Future Work
The in vitro tissue engineered blood vessel mimic (BVM) systems developed in
this thesis and their feasibility for the initial testing of newly emerging intravascular
technologies has been demonstrated. There are limitations that exist with these designs,
however, and the focus of this section is to discuss the limitations of the current models
and future improvements that can be implemented to improve their design.
One design criteria that was not taken into consideration during the Ideal BVM
development was the accommodation of physiological pressure and flow. The current
BVM system setup uses low flow rates and low pressures. The performance of the Ideal
BVM system has not been tested under high pressure, however, the thin compliant
chamber walls may lead to failure. Under high pressure the walls may bellow, due to
their flexibility, creating back pressure within the system. The ability of the lid to remain
tightly sealed may also be compromised. Therefore, to improve the Ideal BVM system
design it may be advantageous to use a container with more rigid walls that do not
deform under high pressure. A stronger latching system may also be needed to prevent
leakage from the lid.
Although stent delivery and deployment were not performed in the Ideal BVM
system designed in this thesis, the procedure remains identical to the original BVM
system. Stent delivery and deployment is performed by inserting a balloon catheter
mounted with a coronary stent into the bioreactor system through the luminal inlet. Flow
is temporarily stopped during the deployment procedure and requires the luminal inlet to
be disconnected from the bioreactor system. It would be advantageous if stent delivery
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and deployment could be performed without disconnecting the BVM system and
stopping flow. One way that this could be accomplished is by attaching a touhy borst
adapter via a Y-connector to a section of tubing leading to the luminal inlet. A touhy
borst adapter allows small diameter devices, such as balloon catheters, to be inserted
through a small seal which prevents leakage at the insertion site. The addition of this
feature could allow stent delivery and deployment to be performed without disrupting
flow within the BVM system and represents a more realistic stenting procedure.
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Conclusion
As discussed in detail throughout this thesis, the blood vessel mimic system has
the potential to help researchers predict the response of human tissue to intravascular
devices prior to animal and clinical testing. The BVM system represents a more realistic
and predictive model that could provide a high-throughput system for assessment of
cellular response to novel intravascular technologies in order to direct animal and clinical
studies toward the most promising devices. The benefits to medical device manufacturers
and more importantly to patients needing these devices would be immense, resulting in
better products reaching patients in a more timely fashion and at lower costs. With
intravascular technologies advancing at a rapid pace, the BVM system has the potential to
one day redefine how intravascular devices, specifically coronary stents, are tested and
developed.
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APPENDIX A: LIST OF ABBREVIATIONS

AAA – Abdominal Aortic Aneurysm
ACC – American College of Cardiology
AHA – American Heart Association
BMS – Bare Metal Stent
BVM – Blood Vessel Mimic
CABG – Coronary Artery Bypass Graft
CAD – Coronary Artery Disease
CHD – Coronary Heart Disease
CT – Computerized Tomography
DES – Drug Eluting Stent
EC – Endothelial Cells
ECG/EKG – Electrocardiogram
ECHO – Echocardiogram
EO – Ethylene Oxide
ePTFE – Expanded Polytetrafluoroethylene
EVAR – Endovascular Aortic Aneurysm Repair
HA – Hyaluronic Acid
HUASMC – Human Umbilical Artery Smooth Muscle Cells
ID – Inner Diameter
ISR – In-stent Restenosis
IVUS – Intravascular Ultrasound
MRI – Magnetic Resonance Imaging
OD – Outer Diameter
PBMA – Poly-n-butyl Methacrylate
PC – Phosphorylcholine
PCI – Percutaneous Coronary Intervention
PCL – Polycaprolactone
PDLA – Poly-D,L-lactic Acid
PET – Positron Emission Tomography
PEVA – Polyethylene-co-vinyl Acetate
PGA – Polyglycolic Acid
PLGA – Polylactic-co-glycolic Acid
PLLA – Poly-L-lactic Acid
P/N – Part Number
PTCA – Percutaneous Transluminal Coronary Angioplasty
SEM – Scanning Electron Microscope
SMC – Smooth Muscle Cells
TEBV – Tissue Engineered Blood Vessels
VSMC – Vascular Smooth Muscle Cells
W – Width
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APPENDIX B: PART INFORMATION AND DRAWINGS

Component
Chamber

Chamber
Buna-N
O-Ring
Loctite 4011
Female Luer
Lug Panel
Mount-1/8"
Barb
Lock Nut
Male Luer
Lock-1/8"
Barb
Female Luer
Thread-1/8"
Barb
Female Luer
Thread-3/32"
Barb
Male-Female
Coupler

Y-Connector1/8" Barbs

1-Way
Stopcock

Description
Polypropylene LeakProof Container,
5"x4"x2", 350 ml
Polypropylene LeakProof Container,
8"x5"x2", 800 ml
Soft Buna-N O-Ring
AS568A Dash
Number 006
Loctite Prism 4011
Medical Adhesive, 20
Gram Bottle
Female Luer Lug Style
Panel Mount 1/4-28
UNF to 200 Series Barb,
1/8" (3.2 mm) ID
Tubing, White Nylon
1/4-28 UNF Panel
Mount Lock Nut,
White Nylon
Male Luer Integral Lock
Ring to 200 Series Barb,
1/8" (3.2 mm) ID
Tubing, White Nylon
Female Luer Thread
Style to 200 Series Barb,
1/8" (3.2 mm) ID
Tubing, White Nylon
Female Luer Thread
Style to 200 Series Barb,
3/32" (2.25 mm) ID
Tubing, White Nylon
Male Luer Integral Lock
Ring to Female Luer
Thread Style Coupler,
White Nylon
Y-Connector with 200
Series Barbs, 1/8" (3.2
mm) ID Tubing,
White Nylon
One-Way Stopcock,
Capped Male Luer Lock
to Capped Female Luer
Thread Style,
Polycarbonate Body w/
Polyethylene Handle

Company

Website

Part Number

Lock &
Lock

www.locknlock.com.au

HPL806

Lock &
Lock

www.locknlock.com.au

HPL816

McMasterCarr

www.mcmaster.com

2418T112

McMasterCarr

www.mcmaster.com

1818A4

Value
Plastics

www.valueplastics.com

FTLB230-1

Value
Plastics

www.valueplastics.com

LNS-1

Value
Plastics

www.valueplastics.com

MTLL230-1

Value
Plastics

www.valueplastics.com

FTLL230-1

Value
Plastics

www.valueplastics.com

FTLL220-1

Value
Plastics

www.valueplastics.com

LC34-1

Value
Plastics

www.valueplastics.com

Y230-1

Value
Plastics

www.valueplastics.com

VP455980

193

3-Way
Stopcock

Male Plug
Male-to-Male
Rotating Luer
50 ml Tube
Silicone
Tubing

Three-Way Stopcock, 2
Capped Female Luer
Thread Style & Capped
Male Luer Lock,
Polycarbonate Body w/
Polyethylene Handle
Male Luer Integral Lock
Ring Plug, Closed at
Grip, White Nylon
Male-to-Male Luer
Connector with One
Rotating Collar, ABS
BD Falcon™ 50 ml
Conical-Bottom
Polypropylene Tube
Tygon® Silicone Tubing
1/8" ID x 1/4" OD

Value
Plastics

www.valueplastics.com

VPB1000079N

Value
Plastics

www.valueplastics.com

LP4-1

Qosina

www.qosina.com

17664

BD
Biosciences

www.bdbiosciences.com

352098

Cole-Parmer

www.coleparmer.com

WU-95702-06
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196

197

198

199

200

201

202

203

204

205

206
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208

209
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APPENDIX C: IDEAL BVM SYSTEM ASSEMBLY

Component

Company

Part Number

Quantity

Leak-Proof Chamber

Lock & Lock

HPL806

1 EA

Buna-N O-Ring

McMaster-Carr

2418T112

6 EA

Loctite 4011 Adhesive

McMaster-Carr

1818A4

3 drops

Female Luer Lug Panel Mount-1/8" Barb

Value Plastics

FTLB230-1

3 EA

Lock Nut

Value Plastics

LNS-1

3 EA

Male Luer Lock-1/8" Barb

Value Plastics

MTLL230-1

2 EA

Female Luer Thread-1/8" Barb

Value Plastics

FTLL230-1

2 EA

Y-Connector-1/8" Barbs

Value Plastics

Y230-1

1 EA

Male-Female Coupler

Value Plastics

LC34-1

2 EA

1-Way Stopcock

Value Plastics

VP455980

2 EA

3-Way Stopcock

Value Plastics

VPB1000079N

1 EA

Male-to-Male Rotating Luer Lock

Qosina

17664

2 EA

Tygon® Silicone Tubing, 1/8" ID

Cole-Parmer

WU-95702-06

11 inches

1. Drill three 15/64" holes into the sides of the leak-proof chamber (Lock & Lock P/N
HPL806).
a. Drill the luminal inlet hole on the
left face of the chamber 1 cm
1 cm

down from the top centered notch
and 1 cm to the right.
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1 cm

b. Drill the luminal outlet hole on the right face of the chamber 1 cm down from
the top centered notch and 1 cm to the left.
c. Drill the extra luminal outlet hole on the right face of the chamber 1 cm down
from the top centered notch and 2 cm to the right.

1 cm
1 cm

2 cm

2. Using a razor blade, remove any plastic
debris that resulted from the use of the
drill from the edges of the holes.

3. Slide a Buna-N o-ring (McMaster-Carr P/N 2418T112)
onto a female luer lug panel mount-1/8" barb (Value
Plastics P/N FTLB230-1).
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4. Thread the female luer lug panel mount with the Buna-N o-ring through the drilled
luminal inlet hole with the barbed portion exiting the side of the chamber.

5. Slide a second Buna-N o-ring (McMaster-Carr P/N 2418T112) onto the barbed end of
the female luer lug panel mount.

6. Tightly screw a lock nut (Value Plastics P/N LNS-1) onto the female luer lug panel
mount, pressing the o-rings against the inside and outside walls of the chamber.
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7. Once securely tightened, place a drop of Loctite
4011 adhesive (McMaster-Carr P/N 1818A4)
between the lock nut and the threaded portion of
the female luer lug panel mount.

8. Repeat steps 3-7 for assembly of the luminal outlet
and extra luminal outlet holes.

9. Attach a 2" piece of Tygon® silicone tubing, 1/8"
ID (Cole-Parmer P/N WU-95702-06) to the barbed
fitting of the luminal inlet.
2"

10. Attach a female luer thread-1/8" ID barb (Value
Plastics P/N FTLL230-1) to the open end of the
silicone tubing attached to the luminal inlet.

11. Secure the male luer lock end of a 3-way stopcock
(Value Plastics P/N VPB1000079N) to the female
luer thread attached to the silicone tubing.
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12. Attach a 5" piece of Tygon® silicone
tubing, 1/8" ID (Cole-Parmer P/N WU95702-06) to the barbed fitting of the
5"

extra luminal outlet.

13. Attach a 1" piece of Tygon® silicone tubing, 1/8" ID
(Cole-Parmer P/N WU-95702-06) to the barbed fitting
of the luminal outlet.

1"

14. Attach a male luer lock-1/8" ID barb (Value Plastics
P/N MTLL230-1) to the open end of the silicone
tubing attached to the luminal outlet.

15. Secure the female luer thread end of a 1-way
stopcock (Value Plastics P/N VP455980) to the male
luer lock attached to the silicone tubing.

16. Attach a female luer thread-1/8" ID barb (Value
Plastics P/N FTLL230-1) to the male luer lock end of
the 1-way stopcock.
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17. Attach a 2" piece of Tygon® silicone tubing,
1/8" ID (Cole-Parmer P/N WU-95702-06) to the
barbed fitting of the female luer thread attached
to the 1-way stopcock.

2"

18. Insert the open ends of the silicone tubing
attached to the luminal outlet and extra luminal
outlet to a Y-connector with 1/8" ID barbs
(Value Plastics P/N Y230-1).

19. Attach a 1" piece of Tygon® silicone tubing,
1/8" ID (Cole-Parmer P/N WU-95702-06) to the
1"

barbed fitting of the Y-connector.

20. Attach a male luer lock-1/8" ID barb (Value
Plastics P/N MTLL230-1) to the open end of the
silicone tubing attached to the Y-connector.

21. Secure the female luer thread end of a 1-way
stopcock (Value Plastics P/N VP455980) to the
male luer lock attached to the silicone tubing.
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22. Place the lid with built in silicone o-ring on the assembled Ideal BVM chamber and
close the four snapping latches.
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APPENDIX D: TWO-PORT MEDIA RESERVOIR ASSEMBLY

Component

Company

Part Number

Quantity

BD Falcon™ 50 ml Tube

BD Biosciences

352098

1 EA

Buna-N O-Ring

McMaster-Carr

2418T112

4 EA

Loctite 4011 Adhesive

McMaster-Carr

1818A4

2 drops

Female Luer Lug Panel Mount-1/8" Barb

Value Plastics

FTLB230-1

2 EA

Lock Nut

Value Plastics

LNS-1

2 EA

Male Luer Lock-1/8" Barb

Value Plastics

MTLL230-1

2 EA

Female Luer Thread-1/8" Barb

Value Plastics

FTLL230-1

1 EA

Tygon® Silicone Tubing, 1/8" ID

Cole-Parmer

WU-95702-06

21 inches

1. Drill two 15/64" holes into the lid of a BD Falcon™ 50
ml tube (BD Biosciences P/N 352098).

2. Using a razor blade, remove any plastic debris that
resulted from the use of the drill from the edges of the holes.

3. Slide a Buna-N o-ring (McMaster-Carr P/N 2418T112)
onto a female luer lug panel mount-1/8" barb (Value
Plastics P/N FTLB230-1).
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4. Thread the female luer lug panel mount with the BunaN o-ring through one of the drilled holes with the
barbed portion exiting the top of the lid.

5. Slide a second Buna-N o-ring (McMaster-Carr P/N
2418T112) onto the barbed end of the female luer lug
panel mount.

6. Tightly screw a lock nut (Value Plastics P/N LNS-1)
onto the female luer lug panel mount, pressing the orings against the top and bottom of the lid.

7. Once securely tightened, place a drop of Loctite 4011
adhesive (McMaster-Carr P/N 1818A4) between the
lock nut and the threaded portion of the female luer lug
panel mount.

8. Repeat steps 3-7 for assembly of the second hole.
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9. Attach a 1" piece of Tygon® silicone tubing, 1/8" ID
(Cole-Parmer P/N WU-95702-06) to a male luer lock1/8" ID barb (Value Plastics P/N MTLL230-1).
1"

10. Secure the male luer lock fitting of the silicone tubing
assembly to one of the female luer lug panel mounts
exiting the bottom of the lid.

11. Attach two 10" pieces of Tygon® silicone tubing, 1/8"
ID (Cole-Parmer P/N WU-95702-06) to the barbed ends
of the female luer lug panel mounts exiting the top of the
lid.
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10"

12. Attach a male luer lock-1/8" ID barb (Value Plastics P/N
MTLL230-1) to the open end of the silicone tubing attached
to the female luer lug panel mount with the 1" silicone tubing
assembly.

13. Attach a female luer thread-1/8" ID barb (Value Plastics P/N
FTLL230-1) to the open end of the silicone tubing attached
to the other female luer lug panel mount.
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14. Screw the bottom section of the BD Falcon™ 50 ml tube to the assembled twoport media reservoir lid.
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APPENDIX E: SCAFFOLD LENGTH VS NUMBER OF COUPLERS USED

Illustration
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# of Couplers

Scaffold Length

0

5.5 cm

1

4.5 cm

2

3.5 cm

APPENDIX F: BVM SYSTEM USER FEEDBACK SURVEY

Name: _________________________
Date: __________________________

1. Overall Usability

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________

2. Setup

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________

3. Scaffold Assembly

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
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4. Scaffold Insertion

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
____________________________________________________________

5. Media Injection

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
____________________________________________________________

6. Seal-ability

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
____________________________________________________________
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7. Aseptic Use

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
____________________________________________________________

8. Bioreactor Assembly

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
____________________________________________________________

9. Control of Flow

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
____________________________________________________________
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10. Adjustability

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
____________________________________________________________

11. Components and Fittings

Awkward

Convenient

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
____________________________________________________________

12. Component Configuration

Poor

Excellent

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
____________________________________________________________
____________________________________________________________
____________________________________________________________
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BVM SYSTEM USER FEEDBACK SURVEY

Dimitri Delagrammaticas
Name: _________________________
Date: __________________________
07/01/08

1. Overall Usability

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
still need a non-sterile partner but fittings and lid make overall use
____________________________________________________________
easier
____________________________________________________________

2. Setup

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
separation of lid from chamber makes setup easier; male and female
____________________________________________________________
fittings ensure correct setup; no air bubbles; no tools needed
____________________________________________________________
3. Scaffold Assembly

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
no difference between old and new BVM; scaffold setup is easy
____________________________________________________________
____________________________________________________________
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4. Scaffold Insertion

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
lid does not have to be held freeing up an extra hand for use; rotating
____________________________________________________________
luer lock fittings make insertion very easy
____________________________________________________________
____________________________________________________________

5. Media Injection

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
media injection is the same for both systems through the three-way
____________________________________________________________
stopcock; air bubbles are easier to eliminate from new chamber but
____________________________________________________________
new chamber requires more media
____________________________________________________________

6. Seal-ability

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
built-in o-ring seal is nice; lid is easy to snap to chamber and creates a strong
____________________________________________________________
leak-proof seal; no tools needed when snapping on lid
____________________________________________________________

____________________________________________________________
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7. Aseptic Use

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
separating the lid from the chamber improves aseptic use; lid can be
____________________________________________________________
sterilized individually
____________________________________________________________
____________________________________________________________

8. Bioreactor Assembly

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
only one way to connect chamber to media reservoir; fast and easy
____________________________________________________________
but new chamber is larger
____________________________________________________________
____________________________________________________________

9. Control of Flow

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
stopcocks are easier to use than side clamps and firmly block flow;
____________________________________________________________
placement of one-way stopcocks makes control of flow easy
____________________________________________________________
____________________________________________________________
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10. Adjustability

Difficult

Easy

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
adjustability is limited to couplers; adjusting with couplers is easy and
____________________________________________________________
provides consistent scaffold lengths
____________________________________________________________
____________________________________________________________

11. Components and Fittings

Awkward

Convenient

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
elimination of UV glue improves component setup; components and
____________________________________________________________
fittings are simple to use
____________________________________________________________
____________________________________________________________

12. Component Configuration

Poor

Excellent

Original BVM

1

2

3

4

5

Ideal BVM

1

2

3

4

5

Comments:
one-way connections to reservoir eliminates the confusion on which
____________________________________________________________
end to connect when assembling the complete bioreactor system;
____________________________________________________________
connection piece used in media reservoir sterilization is eliminated
____________________________________________________________
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APPENDIX G: REPRINT PERMISSIONS
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263
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268

269
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